<?xml version="1.0" encoding="UTF-8"?>
<topic xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
       xmlns:xlink="http://www.w3.org/1999/xlink"
       dx-id="237"
       id="5299b72c-489b-40ac-8f19-2fc096a6fa4a"
       xml:lang="en-gb"
       type="condition">
   <metadata>
      <title>
         <topic-title>Stevens-Johnson syndrome and toxic epidermal necrolysis</topic-title>
      </title>
      <last-updated>2017-06-19T13:54:28.131528Z</last-updated>
      <version-history>
         <version date="2016-07-14">
            <reason update-reason="new-references"/>
            <reason update-reason="new-updated-guidelines"/>
         </version>
         <version date="2015-07-27">
            <reason update-reason="minor-non-clinical-change"/>
         </version>
         <version date="2015-07-27">
            <reason update-reason="new-references"/>
            <reason update-reason="new-updated-guidelines"/>
         </version>
      </version-history>
      <synonyms>
         <synonym displayable="false">Acute toxic epidermolysis</synonym>
         <synonym displayable="false">Erythema multiforme, major</synonym>
         <synonym displayable="false">Exfoliative dermatitis</synonym>
         <synonym displayable="false">Lyell syndrome</synonym>
         <synonym displayable="false">Baader dermatostomatitis</synonym>
         <synonym displayable="false">Ectodermosis erosiva pluriorificialis</synonym>
         <synonym displayable="false">Erythema multiforme bullosum</synonym>
         <synonym displayable="false">Erythema multiforme exudativum</synonym>
         <synonym displayable="false">Febrile mucocutaneous syndrome</synonym>
         <synonym displayable="false">Bullous erythema multiforme</synonym>
         <synonym displayable="false">SJS</synonym>
         <synonym displayable="false">TEN</synonym>
         <synonym displayable="false">STEN</synonym>
         <synonym displayable="true">Erythema multiforme major</synonym>
         <synonym displayable="true">Toxic epidermal necrolysis </synonym>
      </synonyms>
      <related-topics/>
      <categories>
         <category id="3">Critical care medicine</category>
         <category id="4">Dermatology</category>
         <category id="5">Emergency medicine</category>
      </categories>
   </metadata>
   <summary>
      <highlight>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) may be associated with a preceding history of medication use, most commonly anticonvulsants, antibiotics, and non-steroidal anti-inflammatory drugs. Other associated factors include infections.</highlight>
      <highlight>The patient may present with Nikolsky's sign, where the epidermal layer easily sloughs off when pressure is applied to the blistered or erythematous area.</highlight>
      <highlight>Diagnosis is made by clinical presentation and confirmed with skin biopsy.</highlight>
      <highlight>On diagnosis the offending medicine should be stopped. Management is then supportive.</highlight>
      <highlight>Patients do best if they are sent to a burn centre for wound care as soon as the diagnosis is suspected or made.</highlight>
      <highlight>The majority of SJS patients recover (mortality 1% to 5%). SJS can recur either with the same medicine or with another medicine.</highlight>
      <highlight>TEN has a higher mortality (25% to 30%).</highlight>
      <highlight>In the long term, patients should ensure they are not re-exposed to the trigger medicine and be careful of self-medicating. They should avoid sunlight during healing and moisturise their skin.</highlight>
      <highlight>Currently, patients at risk may need HLA screening if they are to receive medications such as carbamazepine, allopurinol, or trimethoprim/sulfamethoxazole.</highlight>
   </summary>
   <content>
      <section name="basics">
         <definition>
            <para>Stevens-Johnson syndrome (SJS) is a severe skin detachment with mucocutaneous complications.<reference ref-id="1">
                  <poc-citation key-article="false" type="article">
                     <citation>Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1922;24:526-533.</citation>
                  </poc-citation>
               </reference> It is an immune reaction to foreign antigens. SJS is a more severe form of erythema multiforme major and a less severe manifestation of toxic epidermal necrolysis (TEN).<reference ref-id="2">
                  <poc-citation key-article="true" type="article">
                     <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                     <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                  </poc-citation>
               </reference> Classification is dependent on the percentage of skin involvement: SJS has &lt;10% total body surface area (TBSA) involvement; SJS/TEN overlap has 10% to 30% TBSA involvement; and TEN has &gt;30% TBSA involvement.<reference ref-id="3">
                  <poc-citation key-article="true" type="article">
                     <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="4">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="5">
                  <poc-citation key-article="true" type="article">
                     <citation>Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="6">
                  <poc-citation key-article="false" type="article">
                     <citation>Auquier-Dunant A, Mockenhaupt M, Maldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="7">
                  <poc-citation key-article="false" type="article">
                     <citation>Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355-361.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="8">
                  <poc-citation key-article="true" type="article">
                     <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="9">
                  <poc-citation key-article="true" type="article">
                     <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                  </poc-citation>
               </reference>
            </para>
         </definition>
         <classifications>
            <classification>
               <title>Cutaneous Involvement Spectrum - clinically accepted classification<reference ref-id="5">
                     <poc-citation key-article="true" type="article">
                        <citation>Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.</citation>
                     </poc-citation>
                  </reference>
                  <reference ref-id="6">
                     <poc-citation key-article="false" type="article">
                        <citation>Auquier-Dunant A, Mockenhaupt M, Maldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.</citation>
                     </poc-citation>
                  </reference>
               </title>
               <detail>
                  <para>There is no formal classification. It is considered that there is a spectrum of exfoliative diseases, with the mild form being erythema multiforme major, the severe form being toxic epidermal necrolysis (TEN), and Stevens-Johnson syndrome (SJS) the mid-point. This has now become a clinically accepted definition and classification of the disease spectrum.</para>
                  <para>Erythema multiforme major</para>
                  <list style="bullet">
                     <item>
                        <para>Target lesions (herpes virus-related)</para>
                     </item>
                  </list>
                  <para>SJS</para>
                  <list style="bullet">
                     <item>
                        <para>&lt;10% total body surface area (TBSA) involvement. Causes include Mycoplasma pneumoniae, viral infections, and vaccines, or drug-related.</para>
                     </item>
                  </list>
                  <para>SJS/TEN overlap</para>
                  <list style="bullet">
                     <item>
                        <para>10% to 30% TBSA involvement. Mainly drug-related.</para>
                     </item>
                  </list>
                  <para>TEN</para>
                  <list style="bullet">
                     <item>
                        <para>&gt;30% TBSA involvement. Drug-related.</para>
                     </item>
                  </list>
               </detail>
            </classification>
         </classifications>
         <vignettes>
            <vignette>
               <para>A 27-year-old man with AIDS presents with a rash that developed over the last 4 days, after being on prophylactic doses of trimethoprim/sulfamethoxazole for 19 days for a CD4 count of &lt;200 lymphocytes. He has a 20% total body surface area (TBSA) skin slough with scattered patches throughout his torso and extremities. Except for conjunctival erythema, he does not have any mucosal involvement. Following successful treatment he is discharged after a 12-day hospital stay. Approximately 2 months after discharge, he takes 'antibiotics for a cold and oral thrush'. He develops a fever, diffuse skin erythema, and pruritus. He presents at hospital 4 hours after taking the medicine, with a blood pressure of 80/40 mmHg, temperature of 40°C (104°F), respiratory rate of 22 breaths per minute, and a heart rate of 96 bpm. It is discovered that the 'antibiotic' was trimethoprim/sulfamethoxazole.</para>
            </vignette>
            <vignette>
               <para>A 14-year-old boy presents with a 1-day history of fever, photophobia, chills, cough, tonsillar enlargement, and chapped, bleeding lips. He has a diffuse erythematous rash including the palms and soles of his feet, in total covering 57% TBSA. <figure fig-id="1">
                     <image-link target="/assets/en-gb/monograph-images/237-2_default.jpg"/>
                     <caption>Stevens-Johnson syndrome: epidermal loss on soles of feet</caption>
                     <source>From the personal collection of Dr A. Kowal-Vern</source>
                  </figure> Within 24 hours the rash progresses to 87% TBSA involvement and the patient requires mechanical ventilation for respiratory distress. He has a history of asthma and has been taking ibuprofen for an upper respiratory infection that developed 2 weeks previously.</para>
            </vignette>
         </vignettes>
         <other-presentations>
            <para>Other highly specific features would be atypical target lesions (which may be confluent), macules, palpable purpuric lesions, or positive Nikolsky's sign (epidermal layer easily sloughs off when pressure is applied to the affected area). Among other presentations, the patient may have fever, malaise, ocular lesions, stomatitis, swelling of the tongue, diarrhoea, vomiting, dysuria, enlarged lymph nodes, arthralgias, arthritis, bronchitis, SOB, wheezing, genital lesions, hypotension, and dehydration.</para>
         </other-presentations>
         <epidemiology>
            <para>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered rare diseases, and there have not been any well-controlled clinical trials or epidemiological studies to determine the exact prevalence and incidence of these conditions. The incidence of SJS is estimated at 1 to 6 cases/million person-years, and 0.4 to 1.2 cases/million person-years for TEN, in all races and ages and both sexes.<reference ref-id="10">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                     <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                  </poc-citation>
               </reference> One case-control study determined that, of the medicines that precipitate SJS and TEN, the antibacterial sulfonamides had an excess risk of 4.5 cases/million exposed people per week.<reference ref-id="10">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                     <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                  </poc-citation>
               </reference> The incidence and prevalence is increased in specific sub-populations that are exposed to particular drugs, such as anticonvulsants in patients with seizures and anti-HIV medicines in HIV-positive individuals, compared with the population not taking those medicines. HIV-positive patients have a combined incidence of SJS and TEN of 1/1000 person-years.<reference ref-id="11">
                  <poc-citation key-article="false" type="article">
                     <citation>Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670-1674.</citation>
                     <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199306103282304#t=article</fulltext-url>
                  </poc-citation>
               </reference>
               <reference ref-id="12">
                  <poc-citation key-article="false" type="article">
                     <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
                  </poc-citation>
               </reference>
            </para>
            <para>One review found that risk estimates based on the number of prescriptions or daily doses ranged from 1 to 10/10,000 new users for carbamazepine, lamotrigine, phenobarbital, and phenytoin, and were lower for valproic acid.<reference ref-id="13">
                  <poc-citation key-article="false" type="article">
                     <citation>Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134-1138.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="14">
                  <poc-citation key-article="false" type="article">
                     <citation>Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.</citation>
                  </poc-citation>
               </reference> Other risk factors for developing SJS/TEN are radiotherapy, collagen vascular disease, transplantation, and herpes infection.<reference ref-id="10">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                     <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                  </poc-citation>
               </reference>
            </para>
            <para>Pharmacogenomic studies indicate that ethnicity and HLA types may predispose patients to adverse drug reactions.<reference ref-id="15">
                  <poc-citation key-article="false" type="article">
                     <citation>Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol. 2015;48:165-175.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="16">
                  <poc-citation key-article="false" type="article">
                     <citation>Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011;50:221-224.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="17">
                  <poc-citation key-article="false" type="article">
                     <citation>Chung WH, Hung SI. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;59:325-332.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="18">
                  <poc-citation key-article="false" type="article">
                     <citation>Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013;94:324-328.</citation>
                     <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748365/</fulltext-url>
                  </poc-citation>
               </reference>
               <reference ref-id="19">
                  <poc-citation key-article="false" type="article">
                     <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                  </poc-citation>
               </reference> HLA-B*1502 allele has a strong association with carbamazepine-induced SJS and TEN in the Han Chinese population; in the US, the FDA recommends testing all Asian people prior to prescribing this medication.<reference ref-id="16">
                  <poc-citation key-article="false" type="article">
                     <citation>Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011;50:221-224.</citation>
                  </poc-citation>
               </reference> HLA-A*0206 and HLA-B*4403 are associated with cold-medicine-related SJS and TEN.<reference ref-id="19">
                  <poc-citation key-article="false" type="article">
                     <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                  </poc-citation>
               </reference> HLA-A*3101 has a strong association with SJS and TEN ocular and other complications regardless of ethnicity.<reference ref-id="15">
                  <poc-citation key-article="false" type="article">
                     <citation>Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol. 2015;48:165-175.</citation>
                  </poc-citation>
               </reference>
               <figure fig-id="2">
                  <image-link target="/assets/en-gb/monograph-images/237-3_default.jpg"/>
                  <caption>Toxic epidermal necrolysis with epidermal loss, ocular involvement, and echthyma gangrenosum</caption>
                  <source>From the personal collection of Dr A. Kowal-Vern</source>
               </figure> All Individuals with HLA-B*5801 are at risk for allopurinol-induced SJS/TENS.<reference ref-id="20">
                  <poc-citation key-article="false" type="article">
                     <citation>Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93:153-158.</citation>
                     <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416/</fulltext-url>
                  </poc-citation>
               </reference>
            </para>
            <para>Presence of HLA-B*1502, HLA-C*0602, or HLA-C*0801 alleles has been associated with trimethoprim/sulfamethoxazole-induced SJS/TEN.<reference ref-id="2">
                  <poc-citation key-article="true" type="article">
                     <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                     <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                  </poc-citation>
               </reference>
               <reference ref-id="21">
                  <poc-citation key-article="false" type="article">
                     <citation>Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25:402-411.</citation>
                  </poc-citation>
               </reference> The US Food and Drug Administration recommends that patients are screened for the HLA-B*5701 allele before starting abacavir for HIV infection.<reference ref-id="22">
                  <poc-citation key-article="false" type="article">
                     <citation>Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18:68-76.</citation>
                     <fulltext-url>http://ejournals.library.ualberta.ca/index.php/JPPS/article/view/23356/18071</fulltext-url>
                  </poc-citation>
               </reference>
            </para>
         </epidemiology>
         <etiology>
            <para>Stevens-Johnson syndrome (SJS) may be a consequence of a disease process, or of an antibiotic, anticonvulsant, or other medicine. A thorough history is essential.</para>
            <para>Several aetiological factors exist.</para>
            <para>1. Infection</para>
            <para>SJS can be a sequela of a number of conditions, including:<reference ref-id="4">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                  </poc-citation>
               </reference>
            </para>
            <list style="bullet">
               <item>
                  <para>Upper respiratory tract infections</para>
               </item>
               <item>
                  <para>Pharyngitis</para>
               </item>
               <item>
                  <para>Otitis media</para>
               </item>
               <item>
                  <para>Mycoplasma pneumoniae</para>
               </item>
               <item>
                  <para>Herpes</para>
               </item>
               <item>
                  <para>EBV</para>
               </item>
               <item>
                  <para>Cytomegaloviruses.<reference ref-id="23">
                        <poc-citation key-article="false" type="article">
                           <citation>Nethercott JR, Choi BC. Erythema multiforme (Stevens Johnson syndrome) chart review of 123 hospitalized patients. Dermatologica. 1985;171:383-396.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </item>
            </list>
            <para>2. Vaccination </para>
            <list style="bullet">
               <item>
                  <para>Smallpox vaccination can precipitate erythema multiforme or SJS.<reference ref-id="24">
                        <poc-citation key-article="false" type="article">
                           <citation>Centers for Disease Control and Prevention. Smallpox fact sheet - information for clinicians: adverse reactions following smallpox vaccination. 2008. http://emergency.cdc.gov (last accessed 21 June 2016).</citation>
                           <fulltext-url>http://emergency.cdc.gov/agent/smallpox/vaccination/reactions-vacc-clinic.asp</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="25">
                        <poc-citation key-article="false" type="article">
                           <citation>Morantz C. CDC releases guidelines for treating adverse reactions to smallpox vaccination. Am Fam Physician. 2003;67:1827, 1829-1830, 1833-1834.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </item>
            </list>
            <para>3. Medicine </para>
            <para>The most frequent drugs implicated in SJS and toxic epidermal necrolysis (TEN) are:<reference ref-id="3">
                  <poc-citation key-article="true" type="article">
                     <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="4">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="10">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                     <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                  </poc-citation>
               </reference>
               <reference ref-id="12">
                  <poc-citation key-article="false" type="article">
                     <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="14">
                  <poc-citation key-article="false" type="article">
                     <citation>Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="19">
                  <poc-citation key-article="false" type="article">
                     <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="26">
                  <poc-citation key-article="false" type="article">
                     <citation>Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-e304.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="27">
                  <poc-citation key-article="false" type="article">
                     <citation>Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="28">
                  <poc-citation key-article="false" type="article">
                     <citation>Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-888.</citation>
                     <fulltext-url>http://jac.oxfordjournals.org/content/62/5/879.full</fulltext-url>
                  </poc-citation>
               </reference>
               <reference ref-id="29">
                  <poc-citation key-article="false" type="article">
                     <citation>La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="30">
                  <poc-citation key-article="false" type="article">
                     <citation>Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="31">
                  <poc-citation key-article="false" type="article">
                     <citation>Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152-158.</citation>
                     <fulltext-url>http://archderm.jamanetwork.com/article.aspx?articleid=1392461</fulltext-url>
                  </poc-citation>
               </reference>
               <reference ref-id="32">
                  <poc-citation key-article="false" type="article">
                     <citation>Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="33">
                  <poc-citation key-article="false" type="article">
                     <citation>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroScar-Study. J Invest Dermatol. 2008;128:35-44.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="34">
                  <poc-citation key-article="false" type="article">
                     <citation>Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47:e16.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="35">
                  <poc-citation key-article="false" type="article">
                     <citation>Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011;5:457-460.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="36">
                  <poc-citation key-article="false" type="article">
                     <citation>Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.</citation>
                     <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/</fulltext-url>
                  </poc-citation>
               </reference>
            </para>
            <list style="bullet">
               <item>
                  <para>Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin, valproic acid, lamotrigine)</para>
               </item>
               <item>
                  <para>Antibiotics (e.g., sulfonamides, aminopenicillins, quinolones, cephalosporins)</para>
               </item>
               <item>Antifungals</item>
               <item>
                  <para>Antiretrovirals (e.g., nevirapine, abacavir) and antivirals (e.g., telaprevir, aciclovir)</para>
               </item>
               <item>
                  <para>Antihelmintics</para>
               </item>
               <item>
                  <para>Analgesics (e.g., paracetamol)</para>
               </item>
               <item>
                  <para>Non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors</para>
               </item>
               <item>
                  <para>Antimalarials</para>
               </item>
               <item>
                  <para>Azathioprine</para>
               </item>
               <item>
                  <para>Sulfasalazine</para>
               </item>
               <item>
                  <para>Allopurinol</para>
               </item>
               <item>
                  <para>Tranexamic acid</para>
               </item>
               <item>
                  <para>Corticosteroids</para>
               </item>
               <item>
                  <para>Psychotropic agents</para>
               </item>
               <item>
                  <para>Chlormezanone</para>
               </item>
               <item>
                  <para>Anticancer drugs (e.g., bendamustine, busulfan, chlorambucil). </para>
               </item>
            </list>
         </etiology>
         <pathophysiology>
            <para>Although there is general agreement that Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) result from an immunological response, the exact pathophysiology of the interactions between drugs, their metabolites, viruses, cytokines, lymphocytes, genetic predisposition, pharmacogenomics, and keratinocyte apoptosis has not been fully unravelled.</para>
            <para>Both SJS and TEN are characterised by the detachment of epidermis from the papillary dermis at the epidermal-dermal junction, manifesting as a papulomacular rash and bullae as a result of keratinocyte apoptosis.<reference ref-id="37">
                  <poc-citation key-article="false" type="article">
                     <citation>Paul C, Wolkenstein PC, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710-714.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="38">
                  <poc-citation key-article="false" type="article">
                     <citation>Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225-230.</citation>
                  </poc-citation>
               </reference>
               <figure fig-id="3">
                  <image-link target="/assets/en-gb/monograph-images/237-4_default.jpg"/>
                  <caption>Histopathology of Stevens-Johnson syndrome/toxic epidermal necrolysis</caption>
                  <source>From the personal collection of Dr A. Kowal-Vern</source>
               </figure> Keratinocyte apoptosis mediated by cytotoxic T-lymphocytes (CD8) in SJS and TENS is modulated by plasma TNF-alpha and interferon-gamma, which are increased in patients with SJS and TEN.<reference ref-id="8">
                  <poc-citation key-article="true" type="article">
                     <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="39">
                  <poc-citation key-article="false" type="article">
                     <citation>Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br. J Dermatol. 2006;155:722-728.</citation>
                  </poc-citation>
               </reference> This process is currently hypothesised to occur through 3 possible pathways: Fas-Fas ligand interaction; perforin/granzyme B; and granulysin-mediated.<reference ref-id="3">
                  <poc-citation key-article="true" type="article">
                     <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="8">
                  <poc-citation key-article="true" type="article">
                     <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="9">
                  <poc-citation key-article="true" type="article">
                     <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="40">
                  <poc-citation key-article="false" type="article">
                     <citation>Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.</citation>
                  </poc-citation>
               </reference>
               <reference ref-id="41">
                  <poc-citation key-article="false" type="article">
                     <citation>Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343-1350.</citation>
                     <fulltext-url>http://www.nature.com/nm/journal/v14/n12/full/nm.1884.html</fulltext-url>
                  </poc-citation>
               </reference>
               <reference ref-id="42">
                  <poc-citation key-article="false" type="article">
                     <citation>Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162:1515-1520.</citation>
                     <fulltext-url>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/S0002-9440%2810%2964284-8/fulltext</fulltext-url>
                  </poc-citation>
               </reference> The main pathway is thought to be granulysin-mediated, but the issue remains controversial and the potential involvement of one or a number of pathways has not been resolved.</para>
            <para>Progress in delineating the pathophysiology of SJS/TEN has addressed the possible risk factors interacting with natural killer (NK) and cytotoxic T-cells, such as drug structure and metabolism (CYP), and the immunogenic characteristics of the HLA molecules.<reference ref-id="2">
                  <poc-citation key-article="true" type="article">
                     <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                     <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                  </poc-citation>
               </reference>
            </para>
            <para>There may be multiple pathways at play depending on the genetic disposition of the patient and/or the type of drug precipitating the immunological response.</para>
         </pathophysiology>
         <risk-factors>
            <risk-factor id="219196-2" strength="strong">
               <name>anticonvulsant medicines</name>
               <detail>
                  <para>The most common anticonvulsants precipitating SJS and TEN are carbamazepine, phenobarbital, phenytoin, lamotrigine, and valproic acid.<reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="14">
                        <poc-citation key-article="false" type="article">
                           <citation>Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.</citation>
                        </poc-citation>
                     </reference> SJS and TEN usually develop in individuals who have started taking the medicine for 1 to 14 days as a new drug; if drugs are used for months or years, the risk for developing SJS and TEN usually occurs in the first 2 months of treatment.<reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference> The index day for developing SJS and TEN is less than a month after starting medication (15 days for carbamazepine, 24 days for phenytoin, 17 days for phenobarbital).<reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference> There may also be genetic factors that predispose these people to have a reaction to the medicine.</para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-3" strength="strong">
               <name>recent infection</name>
               <detail>
                  <para>Mycoplasma pneumoniae has been associated with the development of SJS with &lt;10% total body surface area (TBSA) involvement. Viral infections that have precipitated SJS and erythema multiforme major include: herpes, EBV, and CMV. They can present as ear, nose, and throat infections or with systemic symptoms.<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-4" strength="strong">
               <name>recent antibiotic use</name>
               <detail>
                  <para>The need to treat infection exposes a patient to possible adverse drug reactions with many antibiotics, especially those containing a sulfa derivative. The greatest risk is posed by the use of trimethoprim/sulfamethoxazole and other sulfonamide antibiotics, as well as aminopenicillins, quinolones, and cephalosporins.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="21">
                        <poc-citation key-article="false" type="article">
                           <citation>Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25:402-411.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-5" strength="strong">
               <name>other medicines</name>
               <detail>
                  <para>Other medicines that may put the patient at risk are: antifungals, antivirals (e.g., telaprevir, aciclovir),<reference ref-id="31">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152-158.</citation>
                           <fulltext-url>http://archderm.jamanetwork.com/article.aspx?articleid=1392461</fulltext-url>
                        </poc-citation>
                     </reference> antiretrovirals (e.g., nevirapine, abacavir),<reference ref-id="12">
                        <poc-citation key-article="false" type="article">
                           <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="27">
                        <poc-citation key-article="false" type="article">
                           <citation>Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="28">
                        <poc-citation key-article="false" type="article">
                           <citation>Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-888.</citation>
                           <fulltext-url>http://jac.oxfordjournals.org/content/62/5/879.full</fulltext-url>
                        </poc-citation>
                     </reference> antihelmintics, analgesics (e.g., paracetamol),<reference ref-id="26">
                        <poc-citation key-article="false" type="article">
                           <citation>Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-e304.</citation>
                        </poc-citation>
                     </reference> non-steroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors,<reference ref-id="29">
                        <poc-citation key-article="false" type="article">
                           <citation>La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="30">
                        <poc-citation key-article="false" type="article">
                           <citation>Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696.</citation>
                        </poc-citation>
                     </reference> antimalarials, corticosteroids,<reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference> azathioprine, trimethoprim/sulfamethoxazole, sulfasalazine,<reference ref-id="35">
                        <poc-citation key-article="false" type="article">
                           <citation>Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011;5:457-460.</citation>
                        </poc-citation>
                     </reference> allopurinol, tranexamic acid,<reference ref-id="34">
                        <poc-citation key-article="false" type="article">
                           <citation>Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47:e16.</citation>
                        </poc-citation>
                     </reference> psychotropic agents,<reference ref-id="32">
                        <poc-citation key-article="false" type="article">
                           <citation>Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692.</citation>
                        </poc-citation>
                     </reference> chlormezanone,<reference ref-id="19">
                        <poc-citation key-article="false" type="article">
                           <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="36">
                        <poc-citation key-article="false" type="article">
                           <citation>Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/</fulltext-url>
                        </poc-citation>
                     </reference> and anticancer drugs (e.g., bendamustine, busulfan, chlorambucil).<reference ref-id="36">
                        <poc-citation key-article="false" type="article">
                           <citation>Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-6" strength="strong">
               <name>SLE</name>
               <detail>
                  <para>Seen most frequently with SJS, SJS/TEN overlap, and TEN; not with erythema multiforme major.<reference ref-id="6">
                        <poc-citation key-article="false" type="article">
                           <citation>Auquier-Dunant A, Mockenhaupt M, Maldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.</citation>
                        </poc-citation>
                     </reference> Probable immune interaction with the medicines used to treat SLE, such as corticosteroids and isoniazid.<reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference> The mechanism is most likely to be the drug, but the individual may be genetically susceptible to a reaction to the medicine. It is sometimes difficult to determine if the sheet-like epidermal necrosis is due to SLE or SJS/TEN.<reference ref-id="43">
                        <poc-citation key-article="false" type="article">
                           <citation>Ziemer M, Kardaun SH, Liss Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166:575-600.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-7" strength="strong">
               <name>AIDS</name>
               <detail>
                  <para>Patients are immunocompromised and have multiple drug reactions to their HIV medicines.<reference ref-id="11">
                        <poc-citation key-article="false" type="article">
                           <citation>Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670-1674.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199306103282304#t=article</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="12">
                        <poc-citation key-article="false" type="article">
                           <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="22">
                        <poc-citation key-article="false" type="article">
                           <citation>Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18:68-76.</citation>
                           <fulltext-url>http://ejournals.library.ualberta.ca/index.php/JPPS/article/view/23356/18071</fulltext-url>
                        </poc-citation>
                     </reference> ​Prophylactic use of ​trimethoprim/sulfamethoxazole​ ​to prevent​ Pneumocystis jirovecii pneumonia ​may contribute to increased risk.</para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-8" strength="strong">
               <name>radiotherapy</name>
               <detail>
                  <para>Seen most frequently in oncological patients with recent anticonvulsant medicine during cranial irradiation.<reference ref-id="44">
                        <poc-citation key-article="false" type="article">
                           <citation>Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol. 2014;37:506-513.</citation>
                        </poc-citation>
                     </reference> Amifostine, which is used to protect normal tissues during irradiation and chemotherapy, has also been associated with SJS and TEN.<reference ref-id="45">
                        <poc-citation key-article="false" type="article">
                           <citation>Demiral AN, Yerebakan O, Simsir V, et al. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol. 2002;32:477-479.</citation>
                           <fulltext-url>http://jjco.oxfordjournals.org/cgi/content/full/32/11/477</fulltext-url>
                        </poc-citation>
                     </reference> Patients are immunocompromised from their chemotherapy and the disease process.</para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-9" strength="weak">
               <name>bone marrow transplantation</name>
               <detail>
                  <para>In this context, SJS needs to be differentiated from possible acute graft-versus-host disease (GVHD).<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference> Both conditions start out as a rash. However, in GVHD the skin does not slough off as readily as it does in SJS or TEN. SJS or TEN may result from a drug reaction, whereas GVHD develops after the host lymphocytes attack the donated organ or tissue. It is occasionally difficult to distinguish between GVHD and TEN, particularly because both may occur in a patient in the same timespan. Although extremely rare, most have a high mortality rate. In these cases, SJS/TEN is most frequently drug-related.</para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-10" strength="strong">
               <name>HLA and genetic predisposition </name>
               <detail>
                  <para>Pharmacogenomic studies indicate that ethnicity and HLA types may predispose patients to adverse drug reactions.<reference ref-id="15">
                        <poc-citation key-article="false" type="article">
                           <citation>Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol. 2015;48:165-175.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="16">
                        <poc-citation key-article="false" type="article">
                           <citation>Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011;50:221-224.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="17">
                        <poc-citation key-article="false" type="article">
                           <citation>Chung WH, Hung SI. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;59:325-332.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="18">
                        <poc-citation key-article="false" type="article">
                           <citation>Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013;94:324-328.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748365/</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="19">
                        <poc-citation key-article="false" type="article">
                           <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                        </poc-citation>
                     </reference> HLA-B*1502 allele has a strong association with carbamazepine-induced SJS and TEN in the Han Chinese population; the FDA recommends testing all Asian people prior to prescribing this medication.<reference ref-id="16">
                        <poc-citation key-article="false" type="article">
                           <citation>Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011;50:221-224.</citation>
                        </poc-citation>
                     </reference> HLA-A*0206 and HLA-B*4403 are associated with cold-medicine-related SJS and TEN.<reference ref-id="19">
                        <poc-citation key-article="false" type="article">
                           <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                        </poc-citation>
                     </reference> HLA-A*3101 has a strong association with SJS and TEN ocular and other complications regardless of ethnicity.<reference ref-id="15">
                        <poc-citation key-article="false" type="article">
                           <citation>Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol. 2015;48:165-175.</citation>
                        </poc-citation>
                     </reference>.<figure fig-id="2">
                        <image-link target="/assets/en-gb/monograph-images/237-3_default.jpg"/>
                        <caption>Toxic epidermal necrolysis with epidermal loss, ocular involvement, and echthyma gangrenosum</caption>
                        <source>From the personal collection of Dr A. Kowal-Vern</source>
                     </figure> All Individuals with HLA-B*5801 are at risk for allopurinol-induced SJS/TENS.<reference ref-id="20">
                        <poc-citation key-article="false" type="article">
                           <citation>Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93:153-158.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Presence of HLA-B*1502, HLA-C*0602, or HLA-C*0801 alleles has been associated with trimethoprim/sulfamethoxazole-induced SJS/TEN.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="21">
                        <poc-citation key-article="false" type="article">
                           <citation>Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25:402-411.</citation>
                        </poc-citation>
                     </reference> The US Food and Drug Administration recommends that patients are screened for the HLA-B*5701 allele before starting abacavir for HIV infection.<reference ref-id="22">
                        <poc-citation key-article="false" type="article">
                           <citation>Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18:68-76.</citation>
                           <fulltext-url>http://ejournals.library.ualberta.ca/index.php/JPPS/article/view/23356/18071</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </risk-factor>
            <risk-factor id="219196-11" strength="strong">
               <name>smallpox vaccination</name>
               <detail>
                  <para>Smallpox vaccination is rarely given but it has a well-documented potential to precipitate SJS, which may progress to TEN.<reference ref-id="24">
                        <poc-citation key-article="false" type="article">
                           <citation>Centers for Disease Control and Prevention. Smallpox fact sheet - information for clinicians: adverse reactions following smallpox vaccination. 2008. http://emergency.cdc.gov (last accessed 21 June 2016).</citation>
                           <fulltext-url>http://emergency.cdc.gov/agent/smallpox/vaccination/reactions-vacc-clinic.asp</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="25">
                        <poc-citation key-article="false" type="article">
                           <citation>Morantz C. CDC releases guidelines for treating adverse reactions to smallpox vaccination. Am Fam Physician. 2003;67:1827, 1829-1830, 1833-1834.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </risk-factor>
         </risk-factors>
      </section>
      <section name="diagnosis">
         <approach>
            <section id="219199-19">
               <section-text>
                  <para>Characteristic clinical presentation and skin biopsy results are sufficient to diagnose the condition.</para>
               </section-text>
            </section>
            <section id="219199-20">
               <section-header>History</section-header>
               <section-text>
                  <para>Stevens-Johnson syndrome (SJS) may be a consequence of a disease process or of the antibiotic or other medicine used to treat the condition.<reference ref-id="33">
                        <poc-citation key-article="false" type="article">
                           <citation>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroScar-Study. J Invest Dermatol. 2008;128:35-44.</citation>
                        </poc-citation>
                     </reference> A thorough history is essential, focusing on recent drug or medicine use, recent bacterial or viral infection, and vaccinations. Common historical factors associated with SJS and toxic epidermal necrolysis (TEN) include comorbidities such as seizures, SLE,<reference ref-id="43">
                        <poc-citation key-article="false" type="article">
                           <citation>Ziemer M, Kardaun SH, Liss Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166:575-600.</citation>
                        </poc-citation>
                     </reference> AIDS, collagen vascular disease, and cancer, and certain treatments including radiotherapy<reference ref-id="44">
                        <poc-citation key-article="false" type="article">
                           <citation>Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol. 2014;37:506-513.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="45">
                        <poc-citation key-article="false" type="article">
                           <citation>Demiral AN, Yerebakan O, Simsir V, et al. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol. 2002;32:477-479.</citation>
                           <fulltext-url>http://jjco.oxfordjournals.org/cgi/content/full/32/11/477</fulltext-url>
                        </poc-citation>
                     </reference> and bone marrow transplantation.</para>
                  <para>The most frequent drugs implicated in SJS and TEN are:<reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="12">
                        <poc-citation key-article="false" type="article">
                           <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="14">
                        <poc-citation key-article="false" type="article">
                           <citation>Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="19">
                        <poc-citation key-article="false" type="article">
                           <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="26">
                        <poc-citation key-article="false" type="article">
                           <citation>Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-e304.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="27">
                        <poc-citation key-article="false" type="article">
                           <citation>Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="28">
                        <poc-citation key-article="false" type="article">
                           <citation>Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-888.</citation>
                           <fulltext-url>http://jac.oxfordjournals.org/content/62/5/879.full</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="29">
                        <poc-citation key-article="false" type="article">
                           <citation>La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="30">
                        <poc-citation key-article="false" type="article">
                           <citation>Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="31">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152-158.</citation>
                           <fulltext-url>http://archderm.jamanetwork.com/article.aspx?articleid=1392461</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="32">
                        <poc-citation key-article="false" type="article">
                           <citation>Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="33">
                        <poc-citation key-article="false" type="article">
                           <citation>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroScar-Study. J Invest Dermatol. 2008;128:35-44.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="34">
                        <poc-citation key-article="false" type="article">
                           <citation>Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47:e16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="35">
                        <poc-citation key-article="false" type="article">
                           <citation>Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011;5:457-460.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="36">
                        <poc-citation key-article="false" type="article">
                           <citation>Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <list style="bullet">
                     <item>
                        <para>Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin, valproic acid, lamotrigine)</para>
                     </item>
                     <item>
                        <para>Antibiotics (e.g., sulfonamides, aminopenicillins, quinolones, cephalosporins)</para>
                     </item>
                     <item>
                        <para>Antifungals</para>
                     </item>
                     <item>
                        <para>Antiretrovirals (e.g., nevirapine, abacavir) and antivirals (e.g., telaprevir, aciclovir)</para>
                     </item>
                     <item>
                        <para>Antihelmintics</para>
                     </item>
                     <item>
                        <para>Analgesics (e.g., paracetamol)</para>
                     </item>
                     <item>
                        <para>Non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors</para>
                     </item>
                     <item>
                        <para>Antimalarials</para>
                     </item>
                     <item>
                        <para>Azathioprine</para>
                     </item>
                     <item>
                        <para>Sulfasalazine</para>
                     </item>
                     <item>
                        <para>Allopurinol</para>
                     </item>
                     <item>
                        <para>Tranexamic acid</para>
                     </item>
                     <item>
                        <para>Corticosteroids</para>
                     </item>
                     <item>
                        <para>Psychotropic agents</para>
                     </item>
                     <item>
                        <para>Chlormezanone</para>
                     </item>
                     <item>
                        <para>Anticancer drugs (e.g., bendamustine, busulfan, chlorambucil).</para>
                     </item>
                  </list>
               </section-text>
            </section>
            <section id="219199-21">
               <section-header>Clinical evaluation</section-header>
               <section-text>
                  <para>When seen very early in the course of the disease, signs and symptoms may appear relatively mild. However, the condition typically progresses over a number of days, so close monitoring and regular re-assessment is essential. Transfer to a burn unit should be considered for more severe cases.</para>
                  <para>Cases that present late and those with more severe disease may be in a more critical condition. In these patients, especially, respiratory status should be assessed on admission. One of the potential complications of SJS/TEN is mucosal involvement of the upper and lower respiratory tract, with vesicle formation, ulceration, and actual mucosal sloughing that may lead to laryngeal stridor, along with possible retractions and oedema of the nasopharynx. If there is respiratory distress or oedema of the oropharyngeal tissues, intubation may be necessary to maintain the airway.<reference ref-id="46">
                        <poc-citation key-article="false" type="article">
                           <citation>de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014;42:118-128.</citation>
                        </poc-citation>
                     </reference> Arterial blood gases and oxygen saturation will help to determine patient's clinical respiratory status.</para>
                  <para>More usually, symptoms include a sudden rash or a rash that develops after a new medicine is started. Blisters or macules and flat atypical target lesions,<figure fig-id="4">
                        <image-link target="/assets/en-gb/monograph-images/237-1-hlight_default.jpg"/>
                        <caption>Stevens-Johnson syndrome: targetoid lesions and epidermal loss</caption>
                        <source>From the personal collection of Dr A. Kowal-Vern</source>
                     </figure> diffuse erythema, and Nikolsky's sign (epidermal layer easily sloughs off when pressure is applied to the affected area) may be noted.<reference ref-id="6">
                        <poc-citation key-article="false" type="article">
                           <citation>Auquier-Dunant A, Mockenhaupt M, Maldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.</citation>
                        </poc-citation>
                     </reference> Mucosal involvement presents with erosions or ulceration of the eyes, lips, mouth, pharynx, oesophagus, GI tract, kidneys, liver, anus, genital area, or urethra.</para>
                  <para>Other potential presenting features include fever, swelling of the tongue, diarrhoea, vomiting, dysuria, enlarged lymph nodes, arthralgias, arthritis, bronchitis, SOB, wheezing, hypotension, and dehydration.</para>
                  <para>The patient should be examined as for a burn patient, primarily assessing the status of the airway, breathing, and circulation (ABCs).</para>
                  <para>Assessment of the percentage of body surface area involved is important in classifying SJS or TEN, and various methods have been used. Approximately one hand (palm and fingers) of the patient is the equivalent of 1% total body surface area (TBSA), or alternatively clinicians can use the 'rule of 9s'<reference ref-id="47">
                        <poc-citation key-article="false" type="online">
                           <citation/>
                           <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/figure/fig1/</url>
                        </poc-citation>
                     </reference> or the Lund-Browder burn estimate chart,<reference ref-id="48">
                        <poc-citation key-article="false" type="article">
                           <citation>Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-358.</citation>
                        </poc-citation>
                     </reference> which allow calculation of percentage of body surface affected. A study comparing the reliability of these estimates suggests that the rule of 9s technique often overestimates the burn size and is more variable, but can be performed somewhat faster than the Lund and Browder method.<reference ref-id="49">
                        <poc-citation key-article="false" type="article">
                           <citation>Wachtel TL, Berry CC, Wachtel EE, et al. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000;26:156-170.</citation>
                        </poc-citation>
                     </reference> The scoring system SCORTEN has been found to provide an accurate prediction of mortality in patients with TEN.<reference ref-id="50">
                        <poc-citation key-article="false" type="article">
                           <citation>Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008;29:141-146.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </section-text>
            </section>
            <section id="219199-29">
               <section-header>Wallace's rule of 9s</section-header>
               <section-text>
                  <para>This provides a quick approximation of the area of skin burnt.<reference ref-id="48">
                        <poc-citation key-article="false" type="article">
                           <citation>Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-358.</citation>
                        </poc-citation>
                     </reference> Arbitrarily, it divides the body into units of surface area divisible by 9, with the exception of the perineum. Usually, charts of area are available in most burns units.<reference ref-id="47">
                        <poc-citation key-article="false" type="online">
                           <citation/>
                           <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/figure/fig1/</url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>In an adult, the following are the respective percentages of the total body surface area (TBSA):</para>
                  <list style="bullet">
                     <item>
                        <para>Head and neck total for front and back: 9%</para>
                     </item>
                  </list>
                  <list style="bullet">
                     <item>
                        <para>Each upper limb total for front and back: 9%</para>
                     </item>
                     <item>
                        <para>Thorax and abdomen front: 18%</para>
                     </item>
                     <item>
                        <para>Thorax and abdomen back: 18%</para>
                     </item>
                     <item>
                        <para>Perineum: 1%</para>
                     </item>
                     <item>
                        <para>Each lower limb total for front and back: 18%.</para>
                     </item>
                  </list>
                  <para>The rule of 9s is relatively accurate for adults but not for children, because of the relative disproportion of body-part surface area.</para>
               </section-text>
            </section>
            <section id="219199-30">
               <section-header>Palmar surface</section-header>
               <section-text>
                  <para>The surface area of a patient's palm (including fingers) is roughly 0.8% of total body surface area. Palmar surface can be used to estimate relatively small burns (&lt;15% of total surface area) or very large burns (&gt;85%, when unburnt skin is counted). For medium-sized burns, it is inaccurate.<reference ref-id="51">
                        <poc-citation key-article="false" type="article">
                           <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </section-text>
            </section>
            <section id="219199-31">
               <section-header>Lund-Browder burn estimate chart</section-header>
               <section-text>
                  <para>This chart compensates for the variation in body shape with age, and therefore can give an accurate assessment of burns area in children.<reference ref-id="48">
                        <poc-citation key-article="false" type="article">
                           <citation>Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-358.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="49">
                        <poc-citation key-article="false" type="article">
                           <citation>Wachtel TL, Berry CC, Wachtel EE, et al. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000;26:156-170.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </section-text>
            </section>
            <section id="219199-32">
               <section-header>SCORTEN</section-header>
               <section-text>
                  <para>This severity of illness score is supposed to predict, within the first 5 days of hospitalisation, the risk of mortality for patients who develop SJS/TEN. The patient gets 1 point for each of the following:<reference ref-id="52">
                        <poc-citation key-article="false" type="article">
                           <citation>Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson Syndrome and toxic epidermal necrolysis included in the RegiSCAR Study. J Burn Care Res. 2011;32:237-245.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="53">
                        <poc-citation key-article="true" type="article">
                           <citation>Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126:272-276.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <list style="bullet">
                     <item>
                        <para>&gt;40 years</para>
                     </item>
                     <item>
                        <para>Malignancy</para>
                     </item>
                     <item>
                        <para>&gt;120 bpm tachycardia</para>
                     </item>
                     <item>
                        <para>Initial % TBSA &gt;10%</para>
                     </item>
                     <item>
                        <para>Serum urea &gt;10 mmol/L</para>
                     </item>
                     <item>
                        <para>Serum glucose &gt;14 mmol/L</para>
                     </item>
                     <item>
                        <para>Bicarbonate &lt;20 mmol/L.</para>
                     </item>
                  </list>
                  <para>Although the group originating the SCORTEN score, and some others, have found the scoring system useful,<reference ref-id="54">
                        <poc-citation key-article="false" type="article">
                           <citation>George SM, Harrison DA, Welch CA, et al. Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme Database. Crit Care. 2008;12(suppl 1):S1-S10.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607109/pdf/cc6141.pdf</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="50">
                        <poc-citation key-article="false" type="article">
                           <citation>Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008;29:141-146.</citation>
                        </poc-citation>
                     </reference> others have not.<reference ref-id="55">
                        <poc-citation key-article="false" type="article">
                           <citation>Imahara SD, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006;27:270-275.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>More than likely, the more frequent recent use of intravenous immunoglobulin in these patients has had an impact on some of the validity of this scoring system for TEN.</para>
               </section-text>
            </section>
            <section id="219199-22">
               <section-header>Laboratory evaluation</section-header>
               <section-text>
                  <para>Tests include:</para>
                  <list style="bullet">
                     <item>
                        <para>FBC</para>
                     </item>
                     <item>
                        <para>Blood culture: should be sent to rule out infection with Staphylococcus or Streptococcus species causing toxic shock syndrome or scalded skin syndrome</para>
                     </item>
                     <item>
                        <para>LFTs: are indicated to rule out hepatic damage</para>
                     </item>
                     <item>
                        <para>Arterial blood gases and saturation of oxygen, to assess for respiratory compromise</para>
                     </item>
                     <item>
                        <para>Body surface area affected, which is the best predictor for the presence of bloodstream infection<reference ref-id="56">
                              <poc-citation key-article="false" type="article">
                                 <citation>de Prost N, Ingen-Housz-Oro S, Duong T, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore). 2010;89:28-36.</citation>
                              </poc-citation>
                           </reference>
                        </para>
                     </item>
                     <item>
                        <para>Serum electrolytes and urea, to assess any hypovolaemia</para>
                     </item>
                     <item>
                        <para>Creatinine level: to exclude renal failure.</para>
                     </item>
                  </list>
                  <para>The definitive test for SJS, SJS/TEN overlap, and TEN is a skin biopsy (assessed in conjunction with clinical presentation).<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference> A dermatologist should take a biopsy at the transition point of blistering, to assess the level of skin desquamation. The separation will occur at the epidermal-papillary dermal junction, with the presence of necrotic cells and lymphocytes. Direct immunofluorescence may be performed on the perilesional biopsy to exclude autoimmune blistering disease.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </section-text>
            </section>
         </approach>
         <diagnostic-factors>
            <factor frequency="common"
                    id="219199-1"
                    key-factor="true"
                    type="historical">
               <factor-name>presence of risk factors</factor-name>
               <detail>
                  <para>Key risk factors include anticonvulsant use and the use of certain other medicines, including recent antibiotics; recent infection; conditions such as SLE and AIDS; radiotherapy; smallpox vaccination; and HLA type and Chinese or Japanese ethnicity.</para>
               </detail>
            </factor>
            <factor frequency="common" id="219199-2" key-factor="true" type="sign">
               <factor-name>rash</factor-name>
               <detail>
                  <para>A sudden rash or a rash that develops after a new medicine is started.</para>
               </detail>
            </factor>
            <factor frequency="common" id="219199-3" key-factor="true" type="sign">
               <factor-name>mucosal involvement</factor-name>
               <detail>
                  <para>Erosions or ulceration of the eyes, lips, mouth, pharynx, oesophagus, GI tract, kidneys, liver, anus, genital area, or urethra. More common in Stevens-Johnson syndrome (SJS) than toxic epidermal necrolysis (TEN).</para>
               </detail>
            </factor>
            <factor frequency="uncommon"
                    id="219199-4"
                    key-factor="true"
                    type="sign">
               <factor-name>blisters</factor-name>
               <detail>
                  <para>Blisters or macules and flat atypical target lesions,<figure fig-id="4">
                        <image-link target="/assets/en-gb/monograph-images/237-1-hlight_default.jpg"/>
                        <caption>Stevens-Johnson syndrome: targetoid lesions and epidermal loss</caption>
                        <source>From the personal collection of Dr A. Kowal-Vern</source>
                     </figure> diffuse erythema. More common in TEN than SJS.</para>
               </detail>
            </factor>
            <factor frequency="common" id="219199-5" key-factor="true" type="sign">
               <factor-name>Nikolsky's sign</factor-name>
               <detail>
                  <para>Epidermal layer easily sloughs off when pressure is applied to the affected area. More common in TEN than SJS.</para>
               </detail>
            </factor>
         </diagnostic-factors>
         <tests>
            <test id="219199-6" order="initial" type="pathology">
               <name>skin biopsy</name>
               <result>keratinocyte apoptosis with detachment of the epidermal layer of the skin from the dermal layer</result>
               <detail>
                  <para>The definitive test for diagnosis. It is necessary to get the skin biopsy as soon as possible if there is a suspicion that the patient may have Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).</para>
                  <para>The area of separation may contain a number of CD8-positive T lymphocytes, and the dermis may contain CD4-positive T lymphocytes and macrophages, depending on the stage of the disease when the biopsy is taken.<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                     <figure fig-id="3">
                        <image-link target="/assets/en-gb/monograph-images/237-4_default.jpg"/>
                        <caption>Histopathology of Stevens-Johnson syndrome/toxic epidermal necrolysis</caption>
                        <source>From the personal collection of Dr A. Kowal-Vern</source>
                     </figure>
                  </para>
               </detail>
            </test>
            <test id="219199-7" order="initial" type="pathology">
               <name>blood cultures</name>
               <result>negative in SJS/TEN</result>
               <detail>
                  <para>Necessary to rule out toxic shock syndrome and scalded skin syndrome, which would show positive culture for Staphylococcus or Streptococcus species.</para>
               </detail>
            </test>
            <test id="219199-8" order="initial" type="laboratory">
               <name>FBC</name>
               <result>results depend on the stage at which patients are brought in for testing and the severity of the skin loss. The TEN patients may present with sepsis and an elevated WBC count.</result>
               <detail>
                  <para>If FBC shows eosinophilia, consider hypersensitivity syndrome ([DRESS] drug rash with eosinophilia and systemic symptoms). The WBC count may be elevated if there is a wound infection or sepsis.</para>
               </detail>
            </test>
            <test id="219199-27" order="initial" type="laboratory">
               <name>urea</name>
               <result>may be elevated</result>
               <detail>
                  <para>Elevated urea suggests hypovolaemia.</para>
               </detail>
            </test>
            <test id="219199-28" order="subsequent" type="other">
               <name>serum electrolytes</name>
               <result>hypokalaemia, hyponatraemia</result>
               <detail>
                  <para>Low potassium and sodium levels suggest hypovolaemia.</para>
               </detail>
            </test>
            <test id="219199-33" order="subsequent" type="laboratory">
               <name>serum creatinine</name>
               <result>may be elevated</result>
               <detail>
                  <para>Elevated serum creatinine suggests renal failure or renal disease.</para>
               </detail>
            </test>
            <test id="219199-34" order="subsequent" type="laboratory">
               <name>direct immunofluorescence</name>
               <result>negative</result>
               <detail>
                  <para>Performed on perilesional skin biopsy to exclude autoimmune blistering disease.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </test>
            <test id="219199-9" order="initial" type="laboratory">
               <name>LFTs</name>
               <result>variable abnormalities</result>
               <detail>
                  <para>The exact abnormalities in LFT results depend in part on toxicity of the medication that precipitated the SJS or TEN, as well as on the percentage of total body surface area (TBSA) involvement. Depending on the severity of the SJS or TEN, the inflammatory response produced by the cytokines as a reaction to the insults may be similar to that which occurs in thermal injury: a fatty liver, hepatocyte apoptosis, and necrosis.</para>
               </detail>
            </test>
            <test id="219199-10" order="initial" type="laboratory">
               <name>arterial blood gases and saturation of oxygen</name>
               <result>hypoxaemia, acidosis</result>
               <detail>
                  <para>Arterial blood gases and oxygen saturation will help to determine the patient's clinical respiratory status. One of the complications of SJS/TEN is mucosal involvement of the upper and lower respiratory tract, with vesicle formation, ulceration, and actual mucosal sloughing that may lead to laryngeal stridor, possible retractions, and oedema of the nasopharynx.</para>
               </detail>
            </test>
         </tests>
         <differentials>
            <differential id="219199-11">
               <name>Drug rash with eosinophilia and systemic symptoms (DRESS)</name>
               <sign-symptoms>
                  <para>Presents with fever, rash, lymphadenopathy, arthralgias, hepatitis, nephritis, carditis, eosinophilia, and atypical lymphocytes.<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="57">
                        <poc-citation key-article="false" type="article">
                           <citation>Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="58">
                        <poc-citation key-article="false" type="article">
                           <citation>Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol. 2013;68:709.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Most frequent causative agents are phenytoin, phenobarbital and carbamazepine, and the sulfonamides.<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="59">
                        <poc-citation key-article="false" type="article">
                           <citation>Baba M, Karakas M, Aksunger VL, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol. 2003;17:399-401.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>More frequent among black people.</para>
                  <para>It takes 2 to 6 weeks from beginning the drug therapy to onset of rash.<reference ref-id="5">
                        <poc-citation key-article="true" type="article">
                           <citation>Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy and clinical presentation; FBC may show eosinophilia; LFTs may be elevated if hepatitis present.</para>
               </tests>
            </differential>
            <differential id="219199-12">
               <name>Staphylococcal scalded skin syndrome</name>
               <sign-symptoms>
                  <para>Disease of infancy or early childhood (Ritter's disease).</para>
                  <para>Bacterial endotoxin disrupts the epidermis but without necrosis or inflammation.<reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>FBC, blood and wound cultures, and skin biopsy.</para>
               </tests>
            </differential>
            <differential id="219199-13">
               <name>Toxic shock syndrome</name>
               <sign-symptoms>
                  <para>Either Staphylococcus or Streptococcus can be the origin of the infection, presenting with signs of sepsis and a sunburn-like rash.</para>
               </sign-symptoms>
               <tests>
                  <para>FBC, blood and wound cultures, and skin biopsy.</para>
               </tests>
            </differential>
            <differential id="219199-14">
               <name>Graft versus host disease</name>
               <sign-symptoms>
                  <para>Patients develop a rash, but the skin in graft versus host disease does not slough off as readily as it does in Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).</para>
                  <para>Patients who have been transplanted develop a rash as a result of rejection rather than a drug-induced reaction, although grade IV skin manifestations can be as severe as in TEN. Ocular lesions are rare.<reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>FBC and skin biopsy.</para>
               </tests>
            </differential>
            <differential id="219199-15">
               <name>Vesicant/blister agent poisoning</name>
               <sign-symptoms>
                  <para>Clinical effects such as erythema and blisters will occur immediately with phosgene oxime or lewisite or be delayed for 2 to 24 hours with mustard gas.<reference ref-id="60">
                        <poc-citation key-article="false" type="article">
                           <citation>Centers for Disease Control and Prevention. Toxic syndrome description: vesicant/blister agent poisoning. April 2013. http://www.emergency.cdc.gov (last accessed 21 June 2016).</citation>
                           <fulltext-url>http://emergency.cdc.gov/agent/vesicants/tsd.asp</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy.</para>
               </tests>
            </differential>
            <differential id="219199-16">
               <name>Erythema multiforme</name>
               <sign-symptoms>
                  <para>Target lesions normally triggered by herpes viruses.<reference ref-id="5">
                        <poc-citation key-article="true" type="article">
                           <citation>Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="6">
                        <poc-citation key-article="false" type="article">
                           <citation>Auquier-Dunant A, Mockenhaupt M, Maldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy.</para>
               </tests>
            </differential>
            <differential id="219199-17">
               <name>Burns, skin</name>
               <sign-symptoms>
                  <para>Result of trauma with destruction of the epidermis and dermis to variable degrees.<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy if there is not a good history.</para>
               </tests>
            </differential>
            <differential id="219199-18">
               <name>Paraneoplastic pemphigus</name>
               <sign-symptoms>
                  <para>Blistering disease with a malignant comorbidity.<reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy and direct immunofluorescence.</para>
               </tests>
            </differential>
            <differential id="219199-18">
               <name>Generalised bullous fixed drug eruption (GBFDE)</name>
               <sign-symptoms>
                  <para>History of recurrence in same area when rechallenged with offending drug; few, if any, systemic symptoms; round erythematous or blister patches.<reference ref-id="61">
                        <poc-citation key-article="false" type="article">
                           <citation>Sehgal V, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006; 45:897-908.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="62">
                        <poc-citation key-article="false" type="article">
                           <citation>Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013; 168:726-732.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy.</para>
               </tests>
            </differential>
            <differential id="219199-35">
               <name>Acute generalised exanthematous pustulosis (AGEP)</name>
               <sign-symptoms>
                  <para>Fever, neutrophilia, acute sterile pustules, erythema, facial oedema.<reference ref-id="63">
                        <poc-citation key-article="false" type="article">
                           <citation>Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:260928.</citation>
                           <fulltext-url>http://www.hindawi.com/journals/drp/2015/260928/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy.</para>
               </tests>
            </differential>
            <differential id="219199-36">
               <name>Coxsackievirus A6</name>
               <sign-symptoms>
                  <para>No drug intake; fever; papulovesicles on hands, tongue, buttocks, mouth ulcers.<reference ref-id="64">
                        <poc-citation key-article="false" type="article">
                           <citation>Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013;208:1968-1978.</citation>
                           <fulltext-url>http://jid.oxfordjournals.org/content/208/12/1968.long</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </sign-symptoms>
               <tests>
                  <para>Skin biopsy; virus in skin and blister fluid.</para>
               </tests>
            </differential>
         </differentials>
         <diagnostic-criteria>
            <criteria id="219199-23">
               <title>Erythema multiforme major, SJS, and TEN</title>
               <detail>
                  <para>Erythema multiforme major</para>
                  <list style="bullet">
                     <item>
                        <para>Target lesions (herpes virus-related)</para>
                     </item>
                  </list>
                  <para>SJS</para>
                  <list style="bullet">
                     <item>
                        <para>&lt;10% total body surface area (TBSA) involvement</para>
                     </item>
                  </list>
                  <para>SJS/TEN overlap</para>
                  <list style="bullet">
                     <item>
                        <para>10% to 30% TBSA involvement </para>
                     </item>
                  </list>
                  <para>TEN</para>
                  <list style="bullet">
                     <item>
                        <para>&gt;30% TBSA involvement </para>
                     </item>
                  </list>
               </detail>
            </criteria>
         </diagnostic-criteria>
      </section>
      <section name="treatment">
         <approach>
            <section id="219232-1">
               <section-text>
                  <para>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are similar to second-degree burns in terms of physiological effects. Optimal wound care, nutrition, critical care, and pain management are provided in a specialist burns unit.</para>
                  <para>Exact treatment will depend on the extent of skin involvement, but the same general principles are applicable to both SJS and TEN.</para>
                  <para>Both conditions have a tendency to progress over the course of several days, so all patients should be monitored closely. If the rash is progressing rapidly or the patient is getting worse, the patient should be transferred to a specialist burns unit for care if not already in such a centre.</para>
               </section-text>
            </section>
            <section id="219232-2">
               <section-header>Immediate care</section-header>
               <section-text>
                  <para>Upon diagnosis, the causative agent should be withdrawn immediately. The most frequent drugs implicated in SJS and TEN are:<reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="12">
                        <poc-citation key-article="false" type="article">
                           <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="14">
                        <poc-citation key-article="false" type="article">
                           <citation>Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="19">
                        <poc-citation key-article="false" type="article">
                           <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="26">
                        <poc-citation key-article="false" type="article">
                           <citation>Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-e304.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="27">
                        <poc-citation key-article="false" type="article">
                           <citation>Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="28">
                        <poc-citation key-article="false" type="article">
                           <citation>Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-888.</citation>
                           <fulltext-url>http://jac.oxfordjournals.org/content/62/5/879.full</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="29">
                        <poc-citation key-article="false" type="article">
                           <citation>La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="30">
                        <poc-citation key-article="false" type="article">
                           <citation>Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="31">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152-158.</citation>
                           <fulltext-url>http://archderm.jamanetwork.com/article.aspx?articleid=1392461</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="32">
                        <poc-citation key-article="false" type="article">
                           <citation>Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="33">
                        <poc-citation key-article="false" type="article">
                           <citation>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroScar-Study. J Invest Dermatol. 2008;128:35-44.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="34">
                        <poc-citation key-article="false" type="article">
                           <citation>Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47:e16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="35">
                        <poc-citation key-article="false" type="article">
                           <citation>Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011;5:457-460.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="36">
                        <poc-citation key-article="false" type="article">
                           <citation>Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <list style="bullet">
                     <item>
                        <para>Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin, valproic acid, lamotrigine)</para>
                     </item>
                     <item>
                        <para>Antibiotics (e.g., sulfonamides, aminopenicillins, quinolones, cephalosporins)</para>
                     </item>
                     <item>Antifungals</item>
                     <item>
                        <para>Antiretrovirals (e.g., nevirapine, abacavir) and antivirals (e.g., telaprevir, aciclovir)</para>
                     </item>
                     <item>
                        <para>Antihelmintics</para>
                     </item>
                     <item>
                        <para>Analgesics (e.g., paracetamol)</para>
                     </item>
                     <item>
                        <para>Non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors</para>
                     </item>
                     <item>
                        <para>Antimalarials</para>
                     </item>
                     <item>
                        <para>Azathioprine</para>
                     </item>
                     <item>
                        <para>Sulfasalazine</para>
                     </item>
                     <item>
                        <para>Allopurinol</para>
                     </item>
                     <item>
                        <para>Tranexamic acid</para>
                     </item>
                     <item>
                        <para>Corticosteroids</para>
                     </item>
                     <item>
                        <para>Psychotropic agents</para>
                     </item>
                     <item>
                        <para>Chlormezanone</para>
                     </item>
                     <item>
                        <para>Anticancer drugs (e.g., bendamustine, busulfan, chlorambucil).</para>
                     </item>
                  </list>
                  <para>On admission, the patient is examined to assess airway, breathing, and circulation status (ABCs). It must be determined on admission whether the patient is in respiratory distress. Arterial blood gases and oxygen saturation will help to determine patient clinical respiratory status. One of the complications of SJS/TEN is mucosal involvement of the upper and lower respiratory tract, with vesicle formation, ulceration, and actual mucosal sloughing that may lead to laryngeal stridor, and possible retractions and oedema of the nasopharynx. If there is respiratory distress or oedema of the oropharyngeal tissues, intubation should be used to maintain the airway.<reference ref-id="46">
                        <poc-citation key-article="false" type="article">
                           <citation>de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014;42:118-128.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>An immediate assessment of total body surface area (TBSA) involvement is required. Approximately one hand (palm and fingers) of the patient is the equivalent of 1% TBSA, or use the 'rule of 9s'. The greater the percentage of TBSA involved, the greater the fluid requirement. The burn criteria should be looked at for calculations.<reference ref-id="47">
                        <poc-citation key-article="false" type="online">
                           <citation/>
                           <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/figure/fig1/</url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="48">
                        <poc-citation key-article="false" type="article">
                           <citation>Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-358.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="49">
                        <poc-citation key-article="false" type="article">
                           <citation>Wachtel TL, Berry CC, Wachtel EE, et al. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000;26:156-170.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="51">
                        <poc-citation key-article="false" type="article">
                           <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference> Burn centres that specialise in the critical care needs of these patients should be contacted for advice or possible transfer.</para>
               </section-text>
            </section>
            <section id="219232-16">
               <section-header>Dressings</section-header>
               <section-text>
                  <para>Dressings and topical antibacterial agents should be used to cover cleansed wounds to prevent infection. Choice of dressing is usually determined by physician preference and availability. Depending on the dressing and condition of the wound, dressings should be changed 1 to 2 times a day up to every 2 to 3 days.<reference ref-id="8">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="9">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="51">
                        <poc-citation key-article="false" type="article">
                           <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Dressing options include xenograft (pigskin), allograft (cadaver skin), and man-made dressings. Gauze with bacitracin ointment can also be used, and a cream such as silver sulfadiazine can be combined with a dressing. Silver-imbued man-made dressings can be useful for patients with &gt;30% total body surface area (TBSA) involvement. The silver helps to prevent infection and remains active for 3 to 4 days, allowing less frequent dressing changes. </para>
                  <para>Once the skin has regenerated (after about 2 to 3 weeks), emollients can be useful to keep it supple and prevent drying out. </para>
                  <para>Patients rarely require actual skin grafting. </para>
               </section-text>
            </section>
            <section id="219232-3">
               <section-header>Fluid management</section-header>
               <section-text>
                  <para>If a patient is vomiting frequently, dehydration may occur. In addition, depending on the extent of the skin sloughing, the patient may be losing significant amounts of fluids through the denuded skin surface.</para>
                  <para>If the patient can take fluids orally, they should be encouraged to do so. Otherwise, IV fluids such as lactated Ringer's solution or 0.9% NaCl should be started to hydrate the patient. One case series study indicates that approximately 2 mL/kg/% TBSA may be adequate if there are no other complications.<reference ref-id="65">
                        <poc-citation key-article="false" type="article">
                           <citation>Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31:100-104.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Regardless of the calculated quantity of fluid required, the clinical evaluation of patient response is extremely important. Fluid resuscitation is monitored by urine output. It is important that an adult has a urine output of 0.5 mL/kg/hour (30 to 50 mL/hour) and children weighing &lt;30 kg have an output of 1 mL/kg/hour.</para>
                  <para>Fluid resuscitation should be increased or decreased based on the urine output.</para>
               </section-text>
            </section>
            <section id="219232-4">
               <section-header>Management of pain</section-header>
               <section-text>
                  <para>Pain medicines should be given according to the severity of symptoms. Non-steroidal anti-inflammatory drugs (NSAIDs) should not be used unless other medicines, such as opioids or paracetamol, do not work. Patients will require more pain medicine during dressing changes.</para>
               </section-text>
            </section>
            <section id="219232-5">
               <section-header>Intravenous immunoglobulin (IVIg)</section-header>
               <section-text>
                  <para>There are no clear indications regarding administration of IVIg. Some clinicians give IVIg to patients with a rapidly progressing rash involving at least 6% TBSA. Others only give IVIg when 20% TBSA is affected. There are no definitive randomised controlled trials to guide treatment. The current literature consists of small retrospective and prospective series. Reviews of these small clinical trials have shown some benefit and no major complications with the use of IVIg.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="8">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="9">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="66">
                        <poc-citation key-article="false" type="article">
                           <citation>Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54:108-115.</citation>
                           <fulltext-url>http://onlinelibrary.wiley.com/doi/10.1111/ijd.12423/full</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="67">
                        <poc-citation key-article="false" type="article">
                           <citation>Aires DJ, Fraga G, Korentager R, et al. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol. 2013;12:679-684.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="68">
                        <poc-citation key-article="false" type="article">
                           <citation>Enk A, Eming R, Fierlbeck G et al; European Dermatology Forum Guideline Subcommittee. Guideline on the use of high-dose intravenous immunoglobulin in dermatology (update 2015). 2015. http://www.euroderm.org (last accessed 21 June 2016).</citation>
                           <fulltext-url>http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </section-text>
            </section>
            <section id="219232-6">
               <section-header>Oral involvement</section-header>
               <section-text>
                  <para>In patients with stomatitis who are unable to tolerate eating orally, nutritional support should be administered, feeding the patient either orally or via enteral feeding tube. Hyperalimentation should not be used unless absolutely necessary. A soothing mouthwash should be used for oral hygiene in people with oral mucous membrane involvement.</para>
               </section-text>
            </section>
            <section id="219232-7">
               <section-header>Occupational therapy and physiotherapy</section-header>
               <section-text>
                  <para>Because patients can develop limitations in mobility with decreased strength, they should be ranged daily and exercised within their capability with a physiotherapist and, if needed, occupational therapist.</para>
               </section-text>
            </section>
         </approach>
         <tx-options>
            <tx-option id="3244adfb-198c-4b53-b10d-50d195c60091"
                       timeframe="acute"
                       tx-line="1">
               <pt-group>all patients</pt-group>
               <tx-type>urgent evaluation + withdrawal of causative agent</tx-type>
               <comments>
                  <para>On diagnosis, the causative agent should be withdrawn immediately. The most frequent drugs implicated in SJS and TEN are: anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin, valproic acid, lamotrigine), antibiotics (e.g., sulfonamides, aminopenicillins, quinolones, cephalosporins), antifungals, antiretrovirals (e.g., nevirapine), antivirals (e.g., telaprevir, aciclovir), antihelmintics, analgesics (e.g., paracetamol), non-steroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors, antimalarials, azathioprine, sulfasalazine, allopurinol, tranexamic acid, corticosteroids, psychotropic agents, anticancer drugs (e.g., bendamustine, busulfan, chlorambucil), and chlormezanone.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="3">
                        <poc-citation key-article="true" type="article">
                           <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="4">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="10">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
                           <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="12">
                        <poc-citation key-article="false" type="article">
                           <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="14">
                        <poc-citation key-article="false" type="article">
                           <citation>Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="19">
                        <poc-citation key-article="false" type="article">
                           <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="26">
                        <poc-citation key-article="false" type="article">
                           <citation>Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-e304.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="27">
                        <poc-citation key-article="false" type="article">
                           <citation>Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="28">
                        <poc-citation key-article="false" type="article">
                           <citation>Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-888.</citation>
                           <fulltext-url>http://jac.oxfordjournals.org/content/62/5/879.full</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="29">
                        <poc-citation key-article="false" type="article">
                           <citation>La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="30">
                        <poc-citation key-article="false" type="article">
                           <citation>Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="31">
                        <poc-citation key-article="false" type="article">
                           <citation>Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152-158.</citation>
                           <fulltext-url>http://archderm.jamanetwork.com/article.aspx?articleid=1392461</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="32">
                        <poc-citation key-article="false" type="article">
                           <citation>Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="33">
                        <poc-citation key-article="false" type="article">
                           <citation>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroScar-Study. J Invest Dermatol. 2008;128:35-44.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="34">
                        <poc-citation key-article="false" type="article">
                           <citation>Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47:e16.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="35">
                        <poc-citation key-article="false" type="article">
                           <citation>Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011;5:457-460.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="36">
                        <poc-citation key-article="false" type="article">
                           <citation>Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>On admission, the patient is examined to assess airway, breathing, and circulation status ('ABC'). It must be determined whether the patient is in respiratory distress. Arterial blood gases and oxygen saturation will help to determine patient clinical respiratory status. One of the complications of SJS/TEN is mucosal involvement of the upper and lower respiratory tract, with vesicle formation, ulceration, and actual mucosal sloughing that may lead to laryngeal stridor, and possible retractions and oedema of the nasopharynx: the patient may need to be intubated to maintain the airway.<reference ref-id="46">
                        <poc-citation key-article="false" type="article">
                           <citation>de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014;42:118-128.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>An immediate assessment of total body surface area (TBSA) involvement is required. Approximately one hand (palm and fingers) of the patient is the equivalent of 1% TBSA, or use the 'rule of 9s'. The greater the percentage of TBSA involved, the greater the fluid requirement. The burn criteria should be looked at for calculations.<reference ref-id="47">
                        <poc-citation key-article="false" type="online">
                           <citation/>
                           <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/figure/fig1/</url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="48">
                        <poc-citation key-article="false" type="article">
                           <citation>Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-358.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="49">
                        <poc-citation key-article="false" type="article">
                           <citation>Wachtel TL, Berry CC, Wachtel EE, et al. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000;26:156-170.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="51">
                        <poc-citation key-article="false" type="article">
                           <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference> Burn centres that specialise in the critical care needs of these patients should be contacted for advice or possible transfer.</para>
               </comments>
               <tx-options/>
            </tx-option>
            <tx-option id="14654592-1ac5-435c-837d-aec27ad49220"
                       timeframe="acute"
                       tx-line="P">
               <pt-group>all patients</pt-group>
               <tx-type>dressings + topical antibacterial agents + emollients</tx-type>
               <comments>
                  <para>Dressings and topical antibiotics should be used to cover cleansed wounds to prevent infection. Choice of dressing is usually by physician preference and availability. Depending on the dressing and condition of the wound, dressings should be changed 1 to 2 times a day or every 2 to 3 days.<reference ref-id="8">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="9">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="51">
                        <poc-citation key-article="false" type="article">
                           <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Dressing options include xenograft (pigskin), allograft (cadaver skin), and man-made dressings. Gauze with bacitracin ointment can also be used, and a cream such as silver sulfadiazine can be combined with a dressing. Silver-imbued man-made dressings can be useful for patients with &gt;30% total body surface area (TBSA) involvement. The silver helps to prevent infection and remains active for 3 to 4 days, allowing less frequent dressing changes.</para>
                  <para>Once the skin has regenerated (after about 2 to 3 weeks), emollients can be useful to keep it supple and prevent drying out. </para>
               </comments>
               <regimens>
                  <regimen id="a48d23b0-dff0-463b-a121-ab20d563c18a" tier="1">
                     <components>
                        <component id="6a6f4266-2b46-4cc4-a433-f8b51fb545b2" modifier="unset">
                           <name>bacitracin topical</name>
                           <details>apply to the affected area(s) twice or three times daily</details>
                        </component>
                     </components>
                  </regimen>
                  <regimen id="134c8a7b-7b56-4ab7-b667-776da0fdc252" tier="1">
                     <components>
                        <component id="4d313e3d-9418-4f22-8a6c-3bbed26f8bb1" modifier="unset">
                           <name>silver sulfadiazine topical</name>
                           <details>(1%) apply to the affected area(s) once or twice daily</details>
                        </component>
                     </components>
                  </regimen>
               </regimens>
               <tx-options/>
            </tx-option>
            <tx-option id="787cf9fb-ac40-4126-942a-306ad2260b50"
                       timeframe="acute"
                       tx-line="A">
               <pt-group>all patients</pt-group>
               <tx-type>IV fluids ± nutritional support</tx-type>
               <comments>
                  <para>Patients who can take fluids orally should be encouraged to do so. Otherwise, IV fluids should be started. </para>
                  <para>The greater the percentage of total body surface area (TBSA) involved, the greater the fluid requirement. Patients with 15% to 20% TBSA or more of sloughed skin should receive burn resuscitation fluids. For adults and children &gt;14 years old, &gt;40 kg: 2 to 4 mL lactated Ringer's (LR) solution × kg wt × % TBSA; for children &lt;14 years old, &lt;40 kg: 3 mL LR solution x kg wt x % TBSA; and for infants &lt;10 kg: dextrose 5% in lactated Ringer's solution. Fifty percent of the calculated fluid should be given in the first 8 hours and the rest divided over the next 16 hours.</para>
                  <para>Patients with stomatitis who are unable to tolerate normal eating should be given nutritional support as soon as possible, with feeding either orally or via enteral feeding tube. Parenteral nutrition may be required if enteral feeds are not tolerated.</para>
                  <para>Because of the increased catabolism and hypermetabolism, these patients require a high caloric nutritional supplement: for adults 30 to 35 calories/kg/day, and 1.5 to 2 g/kg/day protein for adults and for children up to 3 g/kg/day. Patients should also receive multivitamins, zinc, vitamin C, and, as needed, magnesium and calcium supplements.</para>
                  <para>For &gt;40% TBSA, consider oxandrolone to reduce the loss of muscle mass and to promote weight gain and healing.<reference ref-id="69">
                        <poc-citation key-article="false" type="article">
                           <citation>Saffle R, Hildreth M. Metabolic support of the burned patient. In: Herndon DN, ed. Total burn care. 2nd ed. New York: W.B. Saunders; 2002:271-287.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </comments>
               <tx-options/>
            </tx-option>
            <tx-option id="58705a8b-d87c-4e35-b2e6-4efc21ebbb6b"
                       timeframe="acute"
                       tx-line="A">
               <pt-group>all patients</pt-group>
               <tx-type>oral hygiene</tx-type>
               <comments>
                  <para>A soothing mouthwash (e.g., lidocaine) should be used for oral hygiene in people with oral mucous membrane involvement.</para>
               </comments>
               <regimens>
                  <regimen id="2f457609-7f09-4d9c-8ccc-a6d857b71c5a" tier="1">
                     <components>
                        <component id="dbd9f77d-77e6-4db3-ba6a-46f7b4c3f213" modifier="unset">
                           <name>lidocaine topical </name>
                           <details>(2% viscous solution) 15 mL every 3 hours when required (swish around in mouth and spit out), maximum 8 doses/day</details>
                        </component>
                     </components>
                  </regimen>
               </regimens>
               <tx-options/>
            </tx-option>
            <tx-option id="9ed6d542-e0c9-4396-a137-163bb39e3a50"
                       timeframe="acute"
                       tx-line="A">
               <pt-group>all patients</pt-group>
               <tx-type>analgesia</tx-type>
               <comments>
                  <para>Doses are titrated according to the severity of symptoms and are also dependent on physician and institutional preference. Non-steroidal anti-inflammatory drugs (NSAIDs) should not be used unless other medicines, such as opioids or paracetamol, do not work.</para>
                  <para>NSAIDs and paracetamol are also known causative agents.</para>
                  <para>Patients will require more pain medicine during dressing changes.</para>
                  <para>Patients may be given a patient-controlled analgesia (PCA) pump, if appropriate.</para>
               </comments>
               <regimens>
                  <regimen id="421d9788-64ca-4f2c-814b-5a89d94e8f85" tier="1">
                     <components>
                        <component id="8994e460-b8e2-46c3-953c-35764f2ea247" modifier="unset">paracetamol<details>children: 10-15 mg/kg orally every 4-6 hours when required, maximum 90 mg/kg/day; adults: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day</details>
                        </component>
                     </components>
                  </regimen>
                  <regimen id="df2f02f1-a0ee-4a14-8040-89e6c4addc82" tier="1">
                     <components>
                        <component id="fb78dbf1-8939-4625-ab1e-df966501fd01" modifier="unset">
                           <name>morphine sulphate</name>
                           <details>children: 0.05 to 0.2 mg/kg orally/intravenously every 2-4 hours when required, maximum 15 mg/kg; adults: 7.5-10 mg orally/intravenously every 4 hours when required</details>
                        </component>
                     </components>
                  </regimen>
               </regimens>
               <tx-options/>
            </tx-option>
            <tx-option id="dedb5578-042e-4c46-a8ed-aa3bd89a5887"
                       timeframe="acute"
                       tx-line="A">
               <pt-group>all patients</pt-group>
               <tx-type>intravenous immunoglobulin (IVIg)</tx-type>
               <comments>
                  <para>There are no clear indications regards administration of IVIg. Some clinicians give IVIg to patients with a rapidly progressing rash involving ≥6% of total body surface area (TBSA). Others only give IVIg when 20% TBSA is affected. There are no definitive randomised controlled trials to guide treatment.</para>
                  <para>IVIg is reserved for patients who have a rapid progression of their mucocutaneous signs and symptoms; comorbidities also determine the type of treatment that the patient will receive.</para>
                  <para>For SJS/TEN overlap and TEN patients, many burn centres give IVIg when there is rapid progression of the rash, and when the patient is clinically deemed a candidate.</para>
                  <para>Particular caution is required in patients with renal impairment.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="68">
                        <poc-citation key-article="false" type="article">
                           <citation>Enk A, Eming R, Fierlbeck G et al; European Dermatology Forum Guideline Subcommittee. Guideline on the use of high-dose intravenous immunoglobulin in dermatology (update 2015). 2015. http://www.euroderm.org (last accessed 21 June 2016).</citation>
                           <fulltext-url>http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Doses used vary widely and are based on literature case reports, anecdotes, and small series.<reference ref-id="9">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="66">
                        <poc-citation key-article="false" type="article">
                           <citation>Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54:108-115.</citation>
                           <fulltext-url>http://onlinelibrary.wiley.com/doi/10.1111/ijd.12423/full</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="67">
                        <poc-citation key-article="false" type="article">
                           <citation>Aires DJ, Fraga G, Korentager R, et al. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol. 2013;12:679-684.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </comments>
               <regimens>
                  <regimen id="21778561-54cf-4368-9747-947054e107ff" tier="1">
                     <components>
                        <component id="d5d7c932-c592-4c06-8920-9cbc445ec029" modifier="unset">
                           <name>intravenous immunoglobulin (IVIG)</name>
                           <details>consult specialist for guidance on dose</details>
                        </component>
                     </components>
                  </regimen>
               </regimens>
               <tx-options/>
            </tx-option>
            <tx-option id="07803968-4bcd-468c-9a48-ee051404b1ce"
                       timeframe="acute"
                       tx-line="A">
               <pt-group>all patients</pt-group>
               <tx-type>physiotherapy and occupational therapy</tx-type>
               <comments>
                  <para>Because patients can develop limitations in mobility with decreased strength, they should be ranged daily and exercised within their capability with a physiotherapist, and, if needed, an occupational therapist.</para>
               </comments>
               <tx-options/>
            </tx-option>
         </tx-options>
         <emerging-txs>
            <emerging-tx id="219232-11">
               <name>Corticosteroids</name>
               <detail>Corticosteroid use has been controversial in Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). There is one uncontrolled study using dexamethasone pulse therapy on 6 patients in the early stages of SJS/TEN. Burn surgeons consider corticosteroid therapy to be contra-indicated in TEN once major skin loss has occurred (&gt;20% total body surface area [TBSA]), especially as corticosteroids themselves can precipitate SJS/TEN.<reference ref-id="4">
                     <poc-citation key-article="false" type="article">
                        <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
                     </poc-citation>
                  </reference>
               </detail>
            </emerging-tx>
            <emerging-tx id="219232-12">
               <name>Plasmapheresis</name>
               <detail>Plasma exchange has been tried in patients with TEN, but the results are equivocal because of small series and few studies. In a 9-year period, 16 patients were treated for TEN: 10 received conventional supportive therapy and 6 were treated with plasmapheresis; none of the plasmapheresed patients died; of the controls, 2 died of sepsis and 2 of cardiopulmonary arrest.<reference ref-id="70">
                     <poc-citation key-article="false" type="article">
                        <citation>Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.</citation>
                     </poc-citation>
                  </reference> The average patient age was 42.4 years; average percentage of TBSA was 51.5%, and the length of hospital stay was 14.8 days.<reference ref-id="70">
                     <poc-citation key-article="false" type="article">
                        <citation>Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.</citation>
                     </poc-citation>
                  </reference> Another study with the successful use of plasmapheresis outside a burn unit involved 13 patients with 17% to 100% TBSA and 1 to 4 mucous membrane lesions.<reference ref-id="71">
                     <poc-citation key-article="false" type="article">
                        <citation>Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002;6:225-228.</citation>
                     </poc-citation>
                  </reference> These patients underwent 2 to 5 plasmapheresis sessions (mean 3.4, exchanging a mean of 10 L of plasma, carried out approximately every other day). Three patients died and 10 recovered.<reference ref-id="71">
                     <poc-citation key-article="false" type="article">
                        <citation>Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002;6:225-228.</citation>
                     </poc-citation>
                  </reference> A study comparing plasmapheresis to 2 published series (no plasmapheresis was given) as controls but with similar age, percentage of TBSA, length of stay, and time to epithelialisation had similar mortality (12.5%) to the 8 patients who received a median of 5.5 plasmapheresis treatments.<reference ref-id="72">
                     <poc-citation key-article="false" type="article">
                        <citation>Furubacke A, Berlin G, Anderson C, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med.1999;25:1307-1310.</citation>
                     </poc-citation>
                  </reference>
               </detail>
            </emerging-tx>
            <emerging-tx id="219232-13">
               <name>Ciclosporin</name>
               <detail>There have been sporadic case reports of successful treatment of TEN with ciclosporin. One small study of ​patients with severe TEN ​(n=11; 83% mean TBSA involvement) found that treatment with ciclosporin resulted in faster cessation of disease progression, shorter time to re-epithelialisation, less organ failure, and less-severe leukopenia, compared with treatment with cyclophosphamide and corticosteroids.<reference ref-id="73">
                     <poc-citation key-article="false" type="article">
                        <citation>Arevalo JM, Lorente JA, Gonzalez-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473-478.</citation>
                     </poc-citation>
                  </reference> In a retrospective chart review of 71 patients with SJS/TEN, ciclosporin was associated with fewer deaths than expected (standardised mortality ratio 0.43) while intravenous immunoglobulin (IVIg) was associated with excess mortality (standardised mortality ratio 1.43).<reference ref-id="74">
                     <poc-citation key-article="false" type="article">
                        <citation>Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71:941-947.</citation>
                     </poc-citation>
                  </reference> Results from a small (n=29) phase II open label trial suggested that ciclosporin could reduce mortality and the progression of epidermal detachment among SJS/TEN patients.<reference ref-id="75">
                     <poc-citation key-article="false" type="article">
                        <citation>Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163:847-853.</citation>
                     </poc-citation>
                  </reference>
               </detail>
            </emerging-tx>
            <emerging-tx id="219232-14">
               <name>Cyclophosphamide</name>
               <detail>Four patients were successfully treated with prednisolone and cyclophosphamide.<reference ref-id="76">
                     <poc-citation key-article="false" type="article">
                        <citation>Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol. 1991;25:778-786.</citation>
                     </poc-citation>
                  </reference> The mechanism was shown to be the inhibition of cell-mediated cytotoxicity.<reference ref-id="76">
                     <poc-citation key-article="false" type="article">
                        <citation>Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol. 1991;25:778-786.</citation>
                     </poc-citation>
                  </reference>
               </detail>
            </emerging-tx>
            <emerging-tx id="219232-17">
               <name>Amniotic membrane ocular coverage</name>
               <detail>Coverage of the entire ocular surface with amniotic membrane, together with intensive short-term topical corticosteroids, during the acute phase of SJS and TEN has been shown to be associated with preservation of good visual acuity and an intact ocular surface.<reference ref-id="77">
                     <poc-citation key-article="false" type="article">
                        <citation>Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149:203-213.</citation>
                     </poc-citation>
                  </reference>
                  <reference ref-id="78">
                     <poc-citation key-article="false" type="article">
                        <citation>Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;18:908-914.</citation>
                     </poc-citation>
                  </reference>
                  <reference ref-id="79">
                     <poc-citation key-article="false" type="article">
                        <citation>Shay E, Kheirkhah A, Liang L, et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol. 2009;54;686-696.</citation>
                        <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853888/</fulltext-url>
                     </poc-citation>
                  </reference>
               </detail>
            </emerging-tx>
            <emerging-tx id="219232-18">
               <name>Cultivated oral mucosa epithelial sheet ocular coverage</name>
               <detail>Cultivated oral mucosal sheet transplantation offers a viable alternative for severe ocular surface diseases due to TEN, chemical, thermal, and other injury.<reference ref-id="80">
                     <poc-citation key-article="false" type="article">
                        <citation>Satake Y, Higa K, Tsubota K, et al. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology. 2011;118:1524-1530.</citation>
                     </poc-citation>
                  </reference>
                  <reference ref-id="81">
                     <poc-citation key-article="false" type="article">
                        <citation>Sotozono C, Inatomi T, Nakamura T, et al. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. Acta Ophthalmol. 2014;92:e447-e453.</citation>
                        <fulltext-url>http://onlinelibrary.wiley.com/doi/10.1111/aos.12397/full</fulltext-url>
                     </poc-citation>
                  </reference>
               </detail>
            </emerging-tx>
         </emerging-txs>
         <guidelines>
            <guideline id="219232-8" region="North America" status="unset">
               <title>Algorithm for burn treatment</title>
               <source>Herndon DN. Total burn care. 4th ed. Philadelphia, PA: Saunders Elsevier; 2012</source>
               <last-published>2012</last-published>
               <summary>
                  <para>Transfer to a burn centre if the patient:<reference ref-id="82">
                        <poc-citation key-article="false" type="article">
                           <citation>Herndon DN, ed. Total burn care. 4th ed. Philadelphia, PA: Elsevier; 2012.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>1. Has a clinical or histological diagnosis of SJS/TEN</para>
                  <para>2. Is a child or is an adult &gt;60 years</para>
                  <para>3. Has a pre-existing medical condition such as diabetes, vascular disease, organ failure, organ transplantation, or HIV</para>
                  <para>4. Has &gt;20% TBSA</para>
                  <para>5. Has rapidly progressing disease.</para>
                  <para>Depending on the severity of skin loss, patients require care as if they had second-degree burns: fluids, nutrition, respiratory care, pain relief, physiotherapy and/or occupational therapy, and antibiotics if they develop a wound, blood, urinary, or pulmonary infection.</para>
               </summary>
            </guideline>
            <guideline id="219232-19" region="North America" status="unset">
               <title>Toxic epidermal necrolysis clinical guidelines</title>
               <source>Harborview Medical Center; US Army Institute of Surgical Research</source>
               <last-published>2008</last-published>
               <url>https://evidencebasedpractice.osumc.edu/Pages/default.aspx</url>
               <summary>
                  <para>Guidelines used at Harborview Medical Center and the US Army Institute of Surgical Research for treating patients with TEN and SJS. </para>
               </summary>
            </guideline>
            <guideline id="219232-15" region="Europe" status="update">
               <title>Guideline on the use of high-dose intravenous immunoglobulin in dermatology (update 2015)</title>
               <source>European Dermatology Forum</source>
               <last-published>2015</last-published>
               <url>http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous</url>
               <summary>
                  <para>Treatment recommendations for the use of IVIg in dermatological conditions, including TEN.</para>
               </summary>
            </guideline>
         </guidelines>
      </section>
      <section name="followup">
         <outlook>
            <section id="219202-1">
               <section-text>
                  <para>Prognosis is best when:</para>
                  <list style="bullet">
                     <item>
                        <para>Patients are &lt;50 years of age</para>
                     </item>
                     <item>
                        <para>The total body surface area (TBSA) involved is low</para>
                     </item>
                     <item>
                        <para>Patients are transferred to a burn centre</para>
                     </item>
                     <item>
                        <para>Patients do not have sepsis</para>
                     </item>
                     <item>
                        <para>Patients do not require antibiotics.</para>
                     </item>
                  </list>
                  <para>A study of paediatric patients with SJS or TEN admitted to a US hospital between 2000 and 2007 reported that 18% had a recurrence of SJS up to 7 years after the initial episode, and 47% had long-term sequelae. The mortality rate was lower than that reported in adults.<reference ref-id="83">
                        <poc-citation key-article="false" type="article">
                           <citation>Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128:723-728.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>A retrospective study of 189 children with SJS over a 29-year period in Thailand reported complications in 20%.<reference ref-id="84">
                        <poc-citation key-article="false" type="article">
                           <citation>Singalavanija S, Limpongsanurak W. Stevens-Johnson syndrome in Thai children: a 29-year study. J Med Assoc Thai. 2011;94(suppl 3):85-90.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </section-text>
            </section>
            <section id="219202-2">
               <section-header>Stevens-Johnson syndrome (SJS)</section-header>
               <section-text>
                  <para>The majority of patients recover, although they may develop some ocular or organ complications residual to the disease; the mortality is 1% to 5%.</para>
               </section-text>
            </section>
            <section id="219202-3">
               <section-header>SJS/TEN overlap</section-header>
               <section-text>
                  <para>The majority of patients recover, although they may develop some complications of ocular or organ origin.</para>
               </section-text>
            </section>
            <section id="219202-4">
               <section-header>TEN</section-header>
               <section-text>
                  <para>The majority of patients recover, although they may develop some ocular or organ complications residual to the disease; the mortality is 25% to 35%.</para>
                  <para>In a multicentre study of 199 toxic epidermal necrolysis (TEN) patients, 64 died. Of the deaths, one third were due to sepsis, one third to multiple organ failure, 14% to cardiopulmonary complications, and 16% were attributed to other causes. Of the 135 survivors, 66% went home, 14% went on to rehabilitation, 7.3% went to an intermediate-care facility, and 7.3% returned to their referring physician.<reference ref-id="85">
                        <poc-citation key-article="false" type="article">
                           <citation>Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87-96.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </section-text>
            </section>
         </outlook>
         <complications>
            <complication id="219202-5" likelihood="high" timeframe="variable">
               <name>infection</name>
               <detail>
                  <para>Loss of skin surface exposes the dermis and increases the risk of infection. Vital signs should be monitored and IV fluids provided. The oropharynx and chapped lips need to be kept as clean as possible.</para>
                  <para>Adhesive bandages should not be used on the exposed skin surfaces.</para>
                  <para>Blood, sputum, and open skin surface cultures should be taken and treatment given according to laboratory sensitivities.</para>
                  <para>If the sloughed skin area is infected, debridement, cleansing the area, antibiotics, and dressing changes are indicated.<reference ref-id="51">
                        <poc-citation key-article="false" type="article">
                           <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Vital signs should be monitored and IV fluids provided.</para>
                  <para>Intubation and ventilator support should be provided if indicated. Chest x-rays should be monitored for information on the healing process.</para>
               </detail>
            </complication>
            <complication id="219202-6" likelihood="high" timeframe="variable">
               <name>ocular complications</name>
               <detail>
                  <para>Ocular complications include pseudomembranous conjunctivitis, tear duct loss, corneal ulcerations, anterior uveitis, dacryocystocele, ectropion, trichiasis, and symblepharon.</para>
                  <para>Reports indicate that patients treated with amniotic membrane transplantation applied to the eyelid margins, palpebral conjunctiva, and ocular surface during the acute phase of SJS or TEN have a decreased risk of significant ocular complications.<reference ref-id="77">
                        <poc-citation key-article="false" type="article">
                           <citation>Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149:203-213.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="78">
                        <poc-citation key-article="false" type="article">
                           <citation>Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;18:908-914.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="79">
                        <poc-citation key-article="false" type="article">
                           <citation>Shay E, Kheirkhah A, Liang L, et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol. 2009;54;686-696.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853888/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>An ophthalmologist should be consulted for diagnosis and recommendations.</para>
               </detail>
            </complication>
            <complication id="219202-7" likelihood="medium" timeframe="long term">
               <name>abnormal skin pigmentation</name>
               <detail>
                  <para>A dermatologist should be consulted for diagnosis and recommendations.</para>
               </detail>
            </complication>
            <complication id="219202-8" likelihood="medium" timeframe="variable">
               <name>nail plate loss</name>
               <detail>
                  <para>Nail beds should be protected until the nail plates regenerate.</para>
               </detail>
            </complication>
            <complication id="219202-9" likelihood="medium" timeframe="variable">
               <name>acute liver failure </name>
               <detail>
                  <para>This could be a response to the medicines that the patient is taking or a response to the development of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Depending on the severity of the SJS or TEN, the inflammatory response produced by the cytokines as a reaction to these insults may be similar to what occurs in thermal injury: a fatty liver, hepatocyte apoptosis, and necrosis. The mechanism for the apoptosis has not been well defined. Necrotic injury may be a result of hypoperfusion or ischaemia-reperfusion. Hepatic injury may also be a part of the constellation of multiple organ failure, especially when sepsis occurs.<reference ref-id="9">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="8">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="86">
                        <poc-citation key-article="false" type="article">
                           <citation>Jeschke MG. The hepatic response to a thermal injury. In: Herndon DN, ed. Total burn care. 2nd ed. New York: W.B. Saunders; 2002:288-299.</citation>
                        </poc-citation>
                     </reference>
                  </para>
                  <para>Enzymes should be monitored to determine whether the patient is recovering and a liver biopsy taken if indicated, based on patient progress during hospitalisation.</para>
               </detail>
            </complication>
            <complication id="219202-10" likelihood="medium" timeframe="variable">
               <name>acute renal failure</name>
               <detail>
                  <para>Renal insults occur, leading to acute tubular necrosis and renal failure either as a result of hypoperfusion or due to the pharmaceutical agents, such as antibiotics, that the patients require, especially when they become septic.</para>
                  <para>Urea and creatinine should be monitored to determine whether the patient is recovering and a renal biopsy taken if indicated, based on patient progress during hospitalisation.<reference ref-id="9">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="8">
                        <poc-citation key-article="true" type="article">
                           <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
                        </poc-citation>
                     </reference>
                     <reference ref-id="87">
                        <poc-citation key-article="false" type="article">
                           <citation>Shinozawa Y, Aikawa N. Renal failure in burn patients. In: Herndon, DN, ed. Total burn care. 2nd ed. New York: W.B. Saunders; 2002:393-398.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </complication>
            <complication id="219202-11" likelihood="high" timeframe="short term">
               <name>dehydration</name>
               <detail>
                  <para>On admission, the hydration status of the patient needs to be assessed. If they have stomatitis, nausea, or vomiting, they are more likely to be dehydrated. Also, depending on the extent of the skin sloughing, they may be losing fluids through their denuded skin surface.</para>
                  <para>If the patient can take fluids orally, they should be encouraged to do so. Otherwise, IV fluids such as lactated Ringer's solution or 0.9% NaCl should be started to hydrate the patient.</para>
                  <para>If the patient has 15% to 20% total body surface area (TBSA) or more of sloughed skin, they should receive burn resuscitation fluids of:</para>
                  <para>2 to 4 mL lactated Ringer's (LR) solution × kg wt × % TBSA for adults and children &gt;14 years old, &gt;40 kg; 3 mL LR solution x kg wt x % TBSA for children &lt;14 years old, &lt;40 kg; and dextrose 5% in lactated Ringer's solution for infants &lt;10 kg.</para>
                  <para>Fifty percent of the calculated fluid should be given in the first 8 hours and the rest divided over the next 16 hours.</para>
                  <para>Regardless of the calculated quantity of fluid for the patient, the clinical evaluation of patient response is extremely important.</para>
                  <para>Fluid resuscitation is monitored by urine output. It is important that an adult has a urine output of 0.5 mL/kg/hour (30 to 50 mL/hour) and children weighing &lt;30 kg have an output of 1 mL/kg/hour. Fluid resuscitation should be increased or decreased based on the urine output.<reference ref-id="51">
                        <poc-citation key-article="false" type="article">
                           <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </complication>
            <complication id="219202-12" likelihood="medium" timeframe="variable">
               <name>hypothermia</name>
               <detail>
                  <para>With the loss of 15% to 20% or more TBSA through sloughing of the skin, patients lose their skin surface thermoregulatory capability. They become hypothermic and require external warming. Hypothermia is detrimental to their circulatory system, coagulation system, and wound healing. Warming can be achieved by increasing the ambient temperature and by using inflatable plastic blankets filled with warm air ('Bair Huggers').</para>
               </detail>
            </complication>
            <complication id="219202-13" likelihood="medium" timeframe="variable">
               <name>vaginal synechiae</name>
               <detail>
                  <para>Hospitalised patients should be seen by a gynaecologist. Those who have not yet reached menopause should follow up with their health practitioner and undergo a pelvic examination to rule out vaginal synechiae within a few months of hospital discharge. Untreated, vaginal synechiae can impair sexual intercourse or normal vaginal delivery.<reference ref-id="2">
                        <poc-citation key-article="true" type="article">
                           <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                           <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                        </poc-citation>
                     </reference>
                     <reference ref-id="88">
                        <poc-citation key-article="false" type="article">
                           <citation>Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4:81-85.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218548/?tool=pubmed</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </complication>
            <complication id="219202-14" likelihood="medium" timeframe="variable">
               <name>pulmonary complications</name>
               <detail>
                  <para>There have been approximately 13 to 16 cases reported of chronic pulmonary complications, which include bronchitis, bronchiolitis obliterans, and bronchiectasis.<reference ref-id="89">
                        <poc-citation key-article="false" type="article">
                           <citation>Kamada N, Kinoshita K, Togawa Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol. 2006;33:616-622.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </complication>
            <complication id="219202-15" likelihood="medium" timeframe="variable">
               <name>ureteral perforation</name>
               <detail>
                  <para>This complication is rare.<reference ref-id="90">
                        <poc-citation key-article="false" type="article">
                           <citation>Baccaro LM, Sakharpe A, Miller A, et al. The first reported case of ureteral perforation in a patient with severe toxic epidermal necrolysis syndrome. J Burn Care Res. 2014;35:e265-e268.</citation>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </complication>
            <complication id="219202-16" likelihood="medium" timeframe="long term">
               <name>acute compartment syndrome</name>
               <detail>
                  <para>This complication is rare but may occur on the extremities or torso.<reference ref-id="91">
                        <poc-citation key-article="false" type="article">
                           <citation>Kamal T, Elnikety S, Mashaly H, et al. Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. J Med Case Rep. 2012;6:84.</citation>
                           <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337800/</fulltext-url>
                        </poc-citation>
                     </reference>
                  </para>
               </detail>
            </complication>
         </complications>
         <recommendations>
            <monitoring>
               <para>There are no specific recommendations, because the health status of each patient on discharge will determine further follow-up.</para>
               <para>If there was ocular involvement, the patient should be seen by an ophthalmologist, and depending on any residual organ damage, they may need to be followed by a specialist such as a pulmonologist, nephrologist, allergist, gastroenterologist, or burn specialist.<reference ref-id="2">
                     <poc-citation key-article="true" type="article">
                        <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                        <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                     </poc-citation>
                  </reference>
               </para>
               <para>Female patients who have not yet reached menopause should follow up with a gynaecologist and undergo a pelvic examination to rule out vaginal synechiae within a few months of hospital discharge. Undiagnosed, vaginal synechiae could impair sexual intercourse or normal vaginal delivery. Prevention of these complications is important.<reference ref-id="2">
                     <poc-citation key-article="true" type="article">
                        <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                        <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                     </poc-citation>
                  </reference>
                  <reference ref-id="88">
                     <poc-citation key-article="false" type="article">
                        <citation>Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4:81-85.</citation>
                        <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218548/?tool=pubmed</fulltext-url>
                     </poc-citation>
                  </reference>
               </para>
               <para>Patients who have difficulty swallowing or mucositis should be seen by an ENT specialist.<reference ref-id="2">
                     <poc-citation key-article="true" type="article">
                        <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
                        <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
                     </poc-citation>
                  </reference>
               </para>
               <para>Because patients can develop limitations in mobility with decreased strength, they should be ranged daily and exercised within their capability with a physiotherapist and, if needed, an occupational therapist.</para>
            </monitoring>
            <patient-instructions>
               <para>The patient should be advised to wear a MedicAlert bracelet.</para>
               <para>Patients who survive Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) should avoid the use of the medicine that initiated the illness.</para>
               <para>Patients should avoid sunlight exposure and sunburn for at least 1 year to promote healing of the skin, especially the areas that were affected by the rash, blisters, or sloughing. They should use a moisturising hydrophilic cream.</para>
            </patient-instructions>
            <preventive-actions>
               <para>Patients who survive SJS or TEN should avoid the use of the medicine that initiated the illness.</para>
               <para>Patients should be alert to any mucosal erosions or ulcerations or rash development. They should be seen by their physician as soon as possible, because SJS has been known to recur several times in the same individuals.</para>
               <para>Because they may have a genetic predisposition, these patients should not self-medicate with antibiotics or over the counter drugs without their physician's approval.</para>
               <para>Any new physician they visit for their health check-ups or problems should be alerted to the fact that they survived either SJS or TEN.</para>
            </preventive-actions>
         </recommendations>
      </section>
      <figures>
         <figure figs-fig-id="1">
            <image-link target="/assets/en-gb/monograph-images/237-2_default.jpg"/>
            <caption>Stevens-Johnson syndrome: epidermal loss on soles of feet</caption>
            <source>From the personal collection of Dr A. Kowal-Vern</source>
         </figure>
         <figure figs-fig-id="2">
            <image-link target="/assets/en-gb/monograph-images/237-3_default.jpg"/>
            <caption>Toxic epidermal necrolysis with epidermal loss, ocular involvement, and echthyma gangrenosum</caption>
            <source>From the personal collection of Dr A. Kowal-Vern</source>
         </figure>
         <figure figs-fig-id="3">
            <image-link target="/assets/en-gb/monograph-images/237-4_default.jpg"/>
            <caption>Histopathology of Stevens-Johnson syndrome/toxic epidermal necrolysis</caption>
            <source>From the personal collection of Dr A. Kowal-Vern</source>
         </figure>
         <figure figs-fig-id="4">
            <image-link target="/assets/en-gb/monograph-images/237-1-hlight_default.jpg"/>
            <caption>Stevens-Johnson syndrome: targetoid lesions and epidermal loss</caption>
            <source>From the personal collection of Dr A. Kowal-Vern</source>
         </figure>
      </figures>
      <references>
         <reference refs-ref-id="1">
            <poc-citation key-article="false" type="article">
               <citation>Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1922;24:526-533.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="2">
            <poc-citation key-article="true" type="article">
               <citation>Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475-493.</citation>
               <fulltext-url>http://rd.springer.com/article/10.1007%2Fs40257-015-0158-0</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="3">
            <poc-citation key-article="true" type="article">
               <citation>Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014;33:10-16.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="4">
            <poc-citation key-article="false" type="article">
               <citation>Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="5">
            <poc-citation key-article="true" type="article">
               <citation>Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-96.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="6">
            <poc-citation key-article="false" type="article">
               <citation>Auquier-Dunant A, Mockenhaupt M, Maldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="7">
            <poc-citation key-article="false" type="article">
               <citation>Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355-361.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="8">
            <poc-citation key-article="true" type="article">
               <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="9">
            <poc-citation key-article="true" type="article">
               <citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="10">
            <poc-citation key-article="false" type="article">
               <citation>Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1608.</citation>
               <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199512143332404#t=article</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="11">
            <poc-citation key-article="false" type="article">
               <citation>Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670-1674.</citation>
               <fulltext-url>http://www.nejm.org/doi/full/10.1056/NEJM199306103282304#t=article</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="12">
            <poc-citation key-article="false" type="article">
               <citation>Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13:49-54.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="13">
            <poc-citation key-article="false" type="article">
               <citation>Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134-1138.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="14">
            <poc-citation key-article="false" type="article">
               <citation>Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63:1012-1019.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="15">
            <poc-citation key-article="false" type="article">
               <citation>Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol. 2015;48:165-175.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="16">
            <poc-citation key-article="false" type="article">
               <citation>Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011;50:221-224.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="17">
            <poc-citation key-article="false" type="article">
               <citation>Chung WH, Hung SI. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010;59:325-332.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="18">
            <poc-citation key-article="false" type="article">
               <citation>Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013;94:324-328.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748365/</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="19">
            <poc-citation key-article="false" type="article">
               <citation>Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015;135:1538-1545.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="20">
            <poc-citation key-article="false" type="article">
               <citation>Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93:153-158.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416/</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="21">
            <poc-citation key-article="false" type="article">
               <citation>Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25:402-411.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="22">
            <poc-citation key-article="false" type="article">
               <citation>Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18:68-76.</citation>
               <fulltext-url>http://ejournals.library.ualberta.ca/index.php/JPPS/article/view/23356/18071</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="23">
            <poc-citation key-article="false" type="article">
               <citation>Nethercott JR, Choi BC. Erythema multiforme (Stevens Johnson syndrome) chart review of 123 hospitalized patients. Dermatologica. 1985;171:383-396.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="24">
            <poc-citation key-article="false" type="article">
               <citation>Centers for Disease Control and Prevention. Smallpox fact sheet - information for clinicians: adverse reactions following smallpox vaccination. 2008. http://emergency.cdc.gov (last accessed 21 June 2016).</citation>
               <fulltext-url>http://emergency.cdc.gov/agent/smallpox/vaccination/reactions-vacc-clinic.asp</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="25">
            <poc-citation key-article="false" type="article">
               <citation>Morantz C. CDC releases guidelines for treating adverse reactions to smallpox vaccination. Am Fam Physician. 2003;67:1827, 1829-1830, 1833-1834.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="26">
            <poc-citation key-article="false" type="article">
               <citation>Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-e304.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="27">
            <poc-citation key-article="false" type="article">
               <citation>Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1-9.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="28">
            <poc-citation key-article="false" type="article">
               <citation>Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-888.</citation>
               <fulltext-url>http://jac.oxfordjournals.org/content/62/5/879.full</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="29">
            <poc-citation key-article="false" type="article">
               <citation>La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28:917-924.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="30">
            <poc-citation key-article="false" type="article">
               <citation>Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29:687-696.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="31">
            <poc-citation key-article="false" type="article">
               <citation>Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013;149:152-158.</citation>
               <fulltext-url>http://archderm.jamanetwork.com/article.aspx?articleid=1392461</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="32">
            <poc-citation key-article="false" type="article">
               <citation>Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8:681-692.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="33">
            <poc-citation key-article="false" type="article">
               <citation>Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroScar-Study. J Invest Dermatol. 2008;128:35-44.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="34">
            <poc-citation key-article="false" type="article">
               <citation>Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013;47:e16.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="35">
            <poc-citation key-article="false" type="article">
               <citation>Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011;5:457-460.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="36">
            <poc-citation key-article="false" type="article">
               <citation>Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25:225-234.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890653/</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="37">
            <poc-citation key-article="false" type="article">
               <citation>Paul C, Wolkenstein PC, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710-714.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="38">
            <poc-citation key-article="false" type="article">
               <citation>Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225-230.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="39">
            <poc-citation key-article="false" type="article">
               <citation>Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br. J Dermatol. 2006;155:722-728.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="40">
            <poc-citation key-article="false" type="article">
               <citation>Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-493.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="41">
            <poc-citation key-article="false" type="article">
               <citation>Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343-1350.</citation>
               <fulltext-url>http://www.nature.com/nm/journal/v14/n12/full/nm.1884.html</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="42">
            <poc-citation key-article="false" type="article">
               <citation>Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162:1515-1520.</citation>
               <fulltext-url>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/S0002-9440%2810%2964284-8/fulltext</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="43">
            <poc-citation key-article="false" type="article">
               <citation>Ziemer M, Kardaun SH, Liss Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166:575-600.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="44">
            <poc-citation key-article="false" type="article">
               <citation>Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol. 2014;37:506-513.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="45">
            <poc-citation key-article="false" type="article">
               <citation>Demiral AN, Yerebakan O, Simsir V, et al. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol. 2002;32:477-479.</citation>
               <fulltext-url>http://jjco.oxfordjournals.org/cgi/content/full/32/11/477</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="46">
            <poc-citation key-article="false" type="article">
               <citation>de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014;42:118-128.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="47">
            <poc-citation key-article="false" type="online">
               <citation/>
               <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/figure/fig1/</url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="48">
            <poc-citation key-article="false" type="article">
               <citation>Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-358.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="49">
            <poc-citation key-article="false" type="article">
               <citation>Wachtel TL, Berry CC, Wachtel EE, et al. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000;26:156-170.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="50">
            <poc-citation key-article="false" type="article">
               <citation>Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008;29:141-146.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="51">
            <poc-citation key-article="false" type="article">
               <citation>Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004;329:101-103.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC449823/?tool=pubmed</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="52">
            <poc-citation key-article="false" type="article">
               <citation>Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson Syndrome and toxic epidermal necrolysis included in the RegiSCAR Study. J Burn Care Res. 2011;32:237-245.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="53">
            <poc-citation key-article="true" type="article">
               <citation>Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126:272-276.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="54">
            <poc-citation key-article="false" type="article">
               <citation>George SM, Harrison DA, Welch CA, et al. Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme Database. Crit Care. 2008;12(suppl 1):S1-S10.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607109/pdf/cc6141.pdf</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="55">
            <poc-citation key-article="false" type="article">
               <citation>Imahara SD, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006;27:270-275.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="56">
            <poc-citation key-article="false" type="article">
               <citation>de Prost N, Ingen-Housz-Oro S, Duong T, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore). 2010;89:28-36.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="57">
            <poc-citation key-article="false" type="article">
               <citation>Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="58">
            <poc-citation key-article="false" type="article">
               <citation>Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol. 2013;68:709.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="59">
            <poc-citation key-article="false" type="article">
               <citation>Baba M, Karakas M, Aksunger VL, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol. 2003;17:399-401.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="60">
            <poc-citation key-article="false" type="article">
               <citation>Centers for Disease Control and Prevention. Toxic syndrome description: vesicant/blister agent poisoning. April 2013. http://www.emergency.cdc.gov (last accessed 21 June 2016).</citation>
               <fulltext-url>http://emergency.cdc.gov/agent/vesicants/tsd.asp</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="61">
            <poc-citation key-article="false" type="article">
               <citation>Sehgal V, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006; 45:897-908.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="62">
            <poc-citation key-article="false" type="article">
               <citation>Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013; 168:726-732.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="63">
            <poc-citation key-article="false" type="article">
               <citation>Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:260928.</citation>
               <fulltext-url>http://www.hindawi.com/journals/drp/2015/260928/</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="64">
            <poc-citation key-article="false" type="article">
               <citation>Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013;208:1968-1978.</citation>
               <fulltext-url>http://jid.oxfordjournals.org/content/208/12/1968.long</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="65">
            <poc-citation key-article="false" type="article">
               <citation>Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010;31:100-104.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="66">
            <poc-citation key-article="false" type="article">
               <citation>Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54:108-115.</citation>
               <fulltext-url>http://onlinelibrary.wiley.com/doi/10.1111/ijd.12423/full</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="67">
            <poc-citation key-article="false" type="article">
               <citation>Aires DJ, Fraga G, Korentager R, et al. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol. 2013;12:679-684.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="68">
            <poc-citation key-article="false" type="article">
               <citation>Enk A, Eming R, Fierlbeck G et al; European Dermatology Forum Guideline Subcommittee. Guideline on the use of high-dose intravenous immunoglobulin in dermatology (update 2015). 2015. http://www.euroderm.org (last accessed 21 June 2016).</citation>
               <fulltext-url>http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="69">
            <poc-citation key-article="false" type="article">
               <citation>Saffle R, Hildreth M. Metabolic support of the burned patient. In: Herndon DN, ed. Total burn care. 2nd ed. New York: W.B. Saunders; 2002:271-287.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="70">
            <poc-citation key-article="false" type="article">
               <citation>Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="71">
            <poc-citation key-article="false" type="article">
               <citation>Bamichas G, Natse T, Christidou F, et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher. 2002;6:225-228.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="72">
            <poc-citation key-article="false" type="article">
               <citation>Furubacke A, Berlin G, Anderson C, et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med.1999;25:1307-1310.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="73">
            <poc-citation key-article="false" type="article">
               <citation>Arevalo JM, Lorente JA, Gonzalez-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48:473-478.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="74">
            <poc-citation key-article="false" type="article">
               <citation>Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71:941-947.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="75">
            <poc-citation key-article="false" type="article">
               <citation>Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163:847-853.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="76">
            <poc-citation key-article="false" type="article">
               <citation>Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol. 1991;25:778-786.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="77">
            <poc-citation key-article="false" type="article">
               <citation>Shammas MC, Lai EC, Sarkar JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149:203-213.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="78">
            <poc-citation key-article="false" type="article">
               <citation>Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;18:908-914.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="79">
            <poc-citation key-article="false" type="article">
               <citation>Shay E, Kheirkhah A, Liang L, et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens Johnson syndrome and toxic epidermal necrolysis. Surv Ophthalmol. 2009;54;686-696.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853888/</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="80">
            <poc-citation key-article="false" type="article">
               <citation>Satake Y, Higa K, Tsubota K, et al. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology. 2011;118:1524-1530.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="81">
            <poc-citation key-article="false" type="article">
               <citation>Sotozono C, Inatomi T, Nakamura T, et al. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. Acta Ophthalmol. 2014;92:e447-e453.</citation>
               <fulltext-url>http://onlinelibrary.wiley.com/doi/10.1111/aos.12397/full</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="82">
            <poc-citation key-article="false" type="article">
               <citation>Herndon DN, ed. Total burn care. 4th ed. Philadelphia, PA: Elsevier; 2012.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="83">
            <poc-citation key-article="false" type="article">
               <citation>Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128:723-728.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="84">
            <poc-citation key-article="false" type="article">
               <citation>Singalavanija S, Limpongsanurak W. Stevens-Johnson syndrome in Thai children: a 29-year study. J Med Assoc Thai. 2011;94(suppl 3):85-90.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="85">
            <poc-citation key-article="false" type="article">
               <citation>Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23:87-96.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="86">
            <poc-citation key-article="false" type="article">
               <citation>Jeschke MG. The hepatic response to a thermal injury. In: Herndon DN, ed. Total burn care. 2nd ed. New York: W.B. Saunders; 2002:288-299.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="87">
            <poc-citation key-article="false" type="article">
               <citation>Shinozawa Y, Aikawa N. Renal failure in burn patients. In: Herndon, DN, ed. Total burn care. 2nd ed. New York: W.B. Saunders; 2002:393-398.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="88">
            <poc-citation key-article="false" type="article">
               <citation>Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011;4:81-85.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218548/?tool=pubmed</fulltext-url>
            </poc-citation>
         </reference>
         <reference refs-ref-id="89">
            <poc-citation key-article="false" type="article">
               <citation>Kamada N, Kinoshita K, Togawa Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol. 2006;33:616-622.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="90">
            <poc-citation key-article="false" type="article">
               <citation>Baccaro LM, Sakharpe A, Miller A, et al. The first reported case of ureteral perforation in a patient with severe toxic epidermal necrolysis syndrome. J Burn Care Res. 2014;35:e265-e268.</citation>
            </poc-citation>
         </reference>
         <reference refs-ref-id="91">
            <poc-citation key-article="false" type="article">
               <citation>Kamal T, Elnikety S, Mashaly H, et al. Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. J Med Case Rep. 2012;6:84.</citation>
               <fulltext-url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337800/</fulltext-url>
            </poc-citation>
         </reference>
      </references>
   </content>
</topic>